Document:

Technology Transfer License Agreement

 Exhibit 10.29 
 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 TECHNOLOGY TRANSFER AND LICENSE AGREEMENT

 This Technology Transfer and License Agreement (“AGREEMENT”) is made between North Dakota State University (hereinafter “NDSU”) and
ALIEN Technology Corporation (hereinafter “ALIEN”). This Agreement shall be effective as of the 17th day
of June, 2002 (“EFFECTIVE DATE”). 
 WITNESSETH 
 WHEREAS, The Defense Microelectronics Activity (“DMEA”) has awarded to NDSU DMEA Contract No. 90-01-C-0009 (hereinafter referred to as “PRIME AWARD”). Phase I of the PRIME AWARD is to support
NDSU’s research and development efforts on NanoBlock® IC and Fluidic Self Assembly (“FSA®”) Technology as part of the Ultra-Low Power Battlefield Sensor Communication System (“ULPBSCS”) Program; 
 WHEREAS, some of the primary objectives under the FULL PROJECT SCOPE OF WORK are to establish a center of excellence at NDSU that is capable of designing and building next–generation netted microsensor systems and to have the Parties
design, develop, and demonstrate affordable next generation sensors integrated into ultra-sensitive receiver/netted data processing systems to enable unprecedented access to real-time information on battlefield conditions; 
 WHEREAS, the Parties acknowledge and agree that to fulfill DMEA’s requirements as described in the PRIME AWARD and FULL PROJECT SCOPE OF WORK the Parties may
collaborate to perform scientific research and development. The Parties agree that desirable by-products of such research and development will be inventions with commercial potential and the creation of businesses near NDSU. 
 WHEREAS, DMEA needs to ensure that it has reliable, long-term access to the design and fabrication of microsensors and sensor systems using the Fluidic Self Assembly
(FSA) process and NanoBlock IC technology from sources other than or in addition to ALIEN, and DMEA has as an objective of the ULPBSCS Program the establishment of a fully capable Center of Excellence for sensor technology at NDSU that is capable of
designing and building next generation netted microsensor systems, and recognizes that this Center of Excellence will be in a position to provide DMEA with long-term, limited-quantity access to such microsensor and sensor system design and
fabrication; 
 WHEREAS, NDSU entered into a subcontract with ALIEN to govern activities to be performed by ALIEN and monies to be paid by NDSU to ALIEN
under this PRIME AWARD Phase I; 
 WHEREAS, NDSU and ALIEN anticipate future DMEA funding will be available beyond PRIME AWARD Phase I, and that such future
DMEA funding may necessitate an additional subcontract with ALIEN to support the FULL PROJECT SCOPE OF WORK; 
 WHEREAS, ALIEN has rights to certain
intellectual property and has developed certain technologies; 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 1 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 WHEREAS, NDSU desires to obtain a license from ALIEN to the intellectual property rights to ALIEN’s FSA and
NanoBlock IC technology for purposes of conducting research that fulfills the DMEA PRIME AWARD, expanding the body of scientific knowledge, facilitating invention creation, and leading to the creation of businesses local to NDSU and the state of
North Dakota that incorporate products based on the results of such research, all on the terms and conditions set forth below; 
 WHEREAS, the Parties
acknowledge and agree that Federal funding is involved in the development of ALIEN’s technologies and intellectual property and in the PRIME AWARD and associated subcontract, and any resulting intellectual property will be subject to certain
government rights and obligations contained in Title 35, U.S. Code, Chapter 18 and its enabling regulations 37 CFR Part 401. 
 NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, Parties hereto agree as follows: 
 ARTICLE 1
— DEFINITIONS 
 For the purposes of this Agreement, the following words and phrases shall have the following meanings: 
  

	1.1	“ALIEN” shall mean Alien Technology Corporation. 

  

	1.2	“ALIEN BACKGROUND INTELLECTUAL PROPERTY” shall mean published and unpublished research and development information, trade secrets, manufacturing methods, designs,
processes, formulations, algorithms, engineering drawings and specifications, know-how, tooling and technical data owned or freely sublicenseable by ALIEN at the EFFECTIVE DATE of this Agreement and reasonably necessary to enable NDSU to design,
test, use, and manufacture the products transferred as described in Section 4.3. 

  

	1.3	“ALIEN CORE TECHNOLOGY,” singular or plural, shall mean both LICENSED PATENTS and ALIEN BACKGROUND INTELLECTUAL PROPERTY. 

  

	1.4	“EFFECTIVE DATE” shall mean the date first written above. 

  

	1.5	“FULL PROJECT SCOPE OF WORK” means DMEA PRIME AWARD and all project or budgetary extensions, modifications or related DMEA awards arising therefrom.

  

	1.6	“LICENSED PATENTS,” singular or plural, shall mean all U.S. patents and patent applications owned or freely sublicenseable by Alien identified and listed in Exhibit
“A” together with all U.S. patent applications filed or still to be filed that draw priority from those patents listed on Exhibit A and all foreign counterparts. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 2 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	1.7	“NDSU BACKGROUND INTELLECTUAL PROPERTY” shall mean published and unpublished research and development information, trade secrets, patents, patent applications, copyright,
manufacturing methods, designs, processes, formulations, algorithms, engineering drawings and specifications, know-how, tooling and technical data owned or freely sublicensable by NDSU as of the EFFECTIVE DATE of this Agreement.

  

	1.8	“RESEARCH PROGRAM” means research activities undertaken to fulfill the FULL PROJECT SCOPE OF WORK or this Agreement. 

  

	1.9	“SENSOR” shall mean a functional product that contains one or more transducers (each of which consists of a single or multi-part component that converts one or more forms
of stimulus or energy into a signal), and that can transmit that signal through wireless or wired circuitry. The purpose of the SENSOR is to measure, by way of example and not limitation, a quantity of pressure, relative humidity, chemical
composition, thermal energy, electromagnetic radiation, or acoustic energy. The signal produced by the transducer is typically electrical, although it may be carried by other means, including but not limited to, optical or magnetic. The signal may
be transmitted by the SENSOR through a variety of means, including wireless (radio, microwave, infrared, etc. frequency) or wired (electrical or optical). In addition to signal transmission, the SENSOR may be capable of receiving signals from other
sources, including other SENSORS. The SENSOR may be capable of independent internal processing of signals produced by transducer components within the SENSOR, and subsequent data or information processing and storage. For purposes of this Agreement,
a tag that functions, in whole or part, in such a way that it competes or may compete, directly or indirectly, with ALIEN’s or its partner’s or licensee’s or customer’s or reseller’s radio frequency identification tag
business is specifically excluded from the definition of SENSOR. 

 ARTICLE 2 — CONFIDENTIAL INFORMATION 
  

	2.1	Close cooperation between the Parties in the conduct of the RESEARCH PROGRAM may require the disclosure by one Party (“DISCLOSING PARTY”) to the other Party
(“RECEIVING PARTY”) of certain proprietary information (“CONFIDENTIAL INFORMATION”). CONFIDENTIAL INFORMATION means any and all inventions, discoveries, trade secrets, knowledge, know-how, practices, process or other information,
machines, components, samples, or other tangible items, disclosed or submitted starting August 2, 2001 by DISCLOSING PARTY to the RECEIVING PARTY and clearly marked or identified as confidential. In order to be protected, CONFIDENTIAL INFORMATION
disclosed orally or in other non-tangible forms, must be (a) identified orally as confidential at the time of disclosure, and (b) summarized in writing and identified as confidential, and (c) such writing must be delivered to the RECEIVING PARTY by
the DISCLOSING PARTY within thirty (30) days of the disclosure that the DISCLOSING PARTY deems confidential. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 3 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	2.2	The obligations of the RECEIVING PARTY to any such information will not apply, however, to information that: 

  

	 	A.	Is generally available to the public at the time of this disclosure; or 

  

	 	B.	Is rightfully known to or in the possession of the RECEIVING PARTY at the time of disclosure without restriction on its disclosure, as shown by competent written evidence; or

  

	 	C.	Is obtained from a third person who insofar as is known rightfully received the information and is not prohibited from transmitting the information by a contractual, legal, or
fiduciary obligation; or 

  

	 	D.	Through no act or omission of the RECEIVING PARTY, is or hereafter becomes part of the public domain; or 

  

	 	E.	The RECEIVING PARTY can prove by written record was developed independently and not based, in whole or in any part, on CONFIDENTIAL INFORMATION furnished by the DISCLOSING PARTY; or

  

	 	F.	Is required to be disclosed by law or regulation, provided however that the Party subject to such disclosure requirement has provided written notice to the DISCLOSING PARTY promptly
to enable the DISCLOSING PARTY to seek a protective order or otherwise prevent or limit disclosure of the CONFIDENTIAL INFORMATION. 

  

	2.3	Specific CONFIDENTIAL INFORMATION disclosed shall not be deemed to be available to the public or in any other party’s prior possession merely because it is embraced by more
general information available to the public or in the other party’s possession. 

  

	2.4	 Until such CONFIDENTIAL INFORMATION falls within an exception under Article 2.2, the RECEIVING PARTY will maintain in confidence and shall not disclose any and
all CONFIDENTIAL INFORMATION received in connection with this Agreement. The RECEIVING PARTY shall not use any CONFIDENTIAL INFORMATION of the DISCLOSING PARTY except as required to perform the RESEARCH PROGRAM. Each Party shall use at least the
same standard of care as it uses to protect its own CONFIDENTIAL INFORMATION, but in no event less than a reasonable standard of care, to ensure that each Party’s students, interns, employees, agents, and consultants do not disclose or make any
unauthorized use of such CONFIDENTIAL INFORMATION. Any student, intern, employee, or consultant of the RECEIVING PARTY must be notified of the restrictions on the use of the DISCLOSING PARTY’s CONFIDENTIAL INFORMATION and must agree in writing
to be bound to terms at least as restrictive as under this Agreement. RECEIVING PARTY shall obtain signed NonDisclosure Agreements from its students, interns, employees, and consultants. Notwithstanding anything to the contrary expressed or implied
elsewhere in this 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 4 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	 
Agreement, DISCLOSING PARTY’s CONFIDENTIAL INFORMATION shall not be shared with nonemployees of a RECEIVING PARTY without the prior written consent of
the DISCLOSING PARTY. 

  

	2.5	It is understood and agreed that CONFIDENTIAL INFORMATION may be shared with the United States government under appropriate confidentiality restrictions pursuant to the
RESEARCH PROGRAM and the PRIME AWARD. 

 ARTICLE 3 — INTELLECTUAL PROPERTY 
  

	3.1	Subject to any limitations imposed by 35 U.S.C. §§ 200-209, any inventions arising out of or in connection with the RESEARCH PROGRAM first conceived or
reduced to practice during the term of this Agreement solely by NDSU personnel shall be the sole property of NDSU (“NDSU SOLELY DEVELOPED INTELLECTUAL PROPERTY”). Any inventions arising out of or in connection with the RESEARCH PROGRAM
first conceived or reduced to practice during the term of this Agreement solely by ALIEN personnel shall be the sole property of ALIEN (“ALIEN SOLELY DEVELOPED INTELLECTUAL PROPERTY”). 

  

	3.2	Subject to any limitations imposed by 35 U.S.C. §§ 200-209, any inventions first conceived or reduced to practice during the term of this Agreement jointly
by the personnel of NDSU and ALIEN shall be jointly owned by the Parties (“JOINTLY DEVELOPED INTELLECTUAL PROPERTY”). 

  

	3.3	Notwithstanding anything to the contrary, inventorship under this Agreement shall be determined in accordance with U.S. Patent Law. 

  

	3.4	NDSU and ALIEN acknowledge that intellectual property rights granted under the terms of this Agreement involve federal funds and other government interests and that the Parties
therefore have obligations under federal and other law. NDSU and ALIEN acknowledge that such obligations under federal law may include, without limitation, the granting of a worldwide, non-exclusive, royalty-free license to the United States
government, and a statement of United States government patent rights on all patents and patent applications. Subject to Article 14, ALIEN acknowledges that any and all determinations of federal funding involvement shall be made solely by NDSU and
NDSU’s reasonable determination shall be honored by ALIEN. Each Party represents and warrants that it (a) has complied and will continue to comply during the term of this Agreement and thereafter with all laws and regulations applicable to
such government funding agreements or government interests and (b) has done and will continue to do during the term of this Agreement and thereafter all acts necessary or convenient for the protection of its rights to retain ownership of all
inventions developed under this Agreement. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 5 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	3.5	Each Party to this Agreement shall obtain appropriate written agreements from all personnel and other entities and individuals involved in the RESEARCH PROGRAM. Such agreements
shall require that all discoveries and inventions conceived or reduced to practice as a result of or in connection with the RESEARCH PROGRAM shall be reported promptly and assigned to the respective Party. 

  

	3.6	Except as expressly provided elsewhere in this Agreement, the Parties retain all title to their respective confidential information and rights and title to their intellectual
property. 

 ARTICLE 4 — LICENSE GRANT TO NDSU 
  

	4.1	Subject to any limitations imposed by 35 U.S.C. §§ 200-209, ALIEN hereby grants to NDSU a nontransferable, nonsublicensable, nonexclusive, royalty free
(includes all fees), license to make and use products or use processes under the LICENSED PATENTS for research and development. Notwithstanding the foregoing, any license for commercial development, including without limitation any manufacture,
importation, use, offer for sale, or sale, shall only be, if at all, pursuant to separate written agreement under Section 5.4. 

  

	4.2	The Parties understand that access to the LICENSED PATENTS may result in the development of products under a funding agreement with the government of the United States and, if so,
that the government may therefore have certain rights under 35 U.S.C. 200 et seq. To the extent that there is a conflict between any such government rights, applicable law or regulation, and this Agreement, the terms of such government
funding agreement, applicable law, or regulation shall prevail. 

  

	4.3	The Parties acknowledge that the subcontracts provide or are expected to provide for ALIEN to transfer to NDSU a desktop FSA tool for research purposes under Phase I and a
semi-automated FSA tool under Phase II, including software and necessary appurtenances, suitable for research purposes and low-level manufacturing, and process documentation. The subcontracts also address or will address the training requirements of
NDSU in using the equipment. Nothing in this Article 4.3 shall be deemed to transfer any ownership interest in any underlying intellectual property rights. 

 ARTICLE 5 — SUBLICENSING AND FIRST OPTION TO LICENSE 
  

	5.1	ALIEN shall have a first option to negotiate an exclusive, royalty-bearing license for an invention that is developed wholly or partly by NDSU, provided that such invention
(1) uses ALIEN CORE TECHNOLOGY; and (2) is either (a) conceived during the term of this Agreement or (b) is reduced to practice during the term of this Agreement. 

  

	5.2	For all inventions subject to Article 5.1, NDSU shall provide written notice to ALIEN of its option to negotiate. Such written notice shall include an invention disclosure statement
drafted in terms consistent with the ordinary practice of NDSU. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 6 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	5.3	Within thirty (30) days of the mailing date of the notice required under Article 5.2, ALIEN shall provide written notice to NDSU of its decision to enter into negotiations for
a license under Article 5.1. If ALIEN does not provide a written notice stating its intention to enter into negotiations within the thirty (30) day period, then NDSU may at that time (but no earlier) enter into negotiations with other parties
and ALIEN shall be deemed to have irrevocably waived its option under Article 5.1 as to that particular invention disclosure. An extension of the response period of this Article 5.3 may be granted at the sole discretion of NDSU and upon the
reasonable request of ALIEN. If the Parties enter into negotiation under this Article and such negotiations do not result in a license agreement between the Parties, then NDSU may not offer a license to any other entity or individual on terms more
favorable than those offered to ALIEN during that negotiation. 

  

	5.4	In the event that ALIEN elects not to invoke its option under this Article or allows the time to respond under Article 5.3 to pass, the Parties agree to the following sublicensing
practices: 

 A. Subject to all terms and conditions of this Agreement, NDSU shall be free to license NDSU SOLELY DEVELOPED
INTELLECTUAL PROPERTY or JOINTLY DEVELOPED INTELLECTUAL PROPERTY under Article 5.1 for the limited field of use of SENSOR. In such cases, and at NDSU’s request, ALIEN shall support NDSU’s commercialization efforts either by, at
ALIEN’s sole option, negotiating in good faith with NDSU a license with the right to sublicense LICENSED PATENTS to or by directly negotiating in good faith a license to LICENSED PATENTS with a company with which NDSU is in active negotiations
to license its NDSU SOLELY DEVELOPED INTELLECTUAL PROPERTY or JOINTLY DEVELOPED INTELLECTUAL PROPERTY (“TARGET COMPANY”). Such (sub)license(s) shall be on commercially reasonable terms and only for the limited field of use of SENSOR so as
to allow TARGET COMPANY to practice NDSU’s SOLELY DEVELOPED INTELLECTUAL PROPERTY or JOINTLY DEVELOPED INTELLECTUAL PROPERTY. Such (sub)license shall in no event be required to have an effective date earlier than the effective date of the
TARGET COMPANY’s license from NDSU to NDSU SOLELY DEVELOPED INTELLECTUAL PROPERTY or JOINTLY DEVELOPED INTELLECTUAL PROPERTY. Such a license shall not be unreasonably withheld by ALIEN. Except as expressly required elsewhere in this Agreement,
ALIEN shall not be required to nor may NDSU disclose any ALIEN CONFIDENTIAL INFORMATION to TARGET COMPANY without ALIEN’s written permission. At ALIEN’s request, NDSU shall promptly provide evidence of active negotiations. 
 B. Subject to the terms and conditions of this Agreement, in areas other than SENSOR where the licensed use of an invention under Article 5.1 would be in
an area identified in good faith by ALIEN, in ALIEN’s sole discretion, as not competitive to ALIEN (including without limitation competitive to ALIEN’s licensees or partners) and where ALIEN is not restricted by other licenses with third
parties from licensing or sublicensing its technology to a TARGET COMPANY, including the U.S. government, NDSU shall be free to license NDSU SOLELY DEVELOPED INTELLECTUAL PROPERTY or 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 7 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
JOINTLY DEVELOPED INTELLECTUAL PROPERTY. In such cases, and at NDSU’s request, ALIEN shall support NDSU’s commercialization efforts either by, at
ALIEN’s sole option, negotiating in good faith with NDSU a license with the right to sublicense LICENSED PATENTS to or by directly negotiating in good faith a license to LICENSED PATENTS with a TARGET COMPANY. Such (sub)license(s) shall be on
commercially reasonable terms and only for a limited field of use so as to allow TARGET COMPANY to practice NDSU’s SOLELY DEVELOPED INTELLECTUAL PROPERTY or JOINTLY DEVELOPED INTELLECTUAL PROPERTY. Such license shall in no event be required to
have an effective date earlier than the effective date of the TARGET COMPANY’s license from NDSU to NDSU SOLELY DEVELOPED INTELLECTUAL PROPERTY or JOINTLY DEVELOPED INTELLECTUAL PROPERTY. Such a license shall not be unreasonably withheld by
ALIEN. Except as expressly required elsewhere in this Agreement, ALIEN shall not be required to nor may NDSU disclose any ALIEN CONFIDENTIAL INFORMATION to TARGET COMPANY without ALIEN’s written permission. At ALIEN’s request, NDSU shall
promptly provide evidence of active negotiations. 
 C. Notwithstanding the foregoing Articles 5.4A. and 5.4B., if the NDSU SOLELY DEVELOPED
INTELLECTUAL PROPERTY or JOINTLY DEVELOPED INTELLECTUAL PROPERTY under Article 5.1, (a) is not a SENSOR and (b) ALIEN is restricted by other licenses with third parties from licensing or sublicensing its technology to a TARGET COMPANY,
NDSU may request ALIEN’s consideration of cooperation in commercialization. ALIEN will consider such requests on a case-by-case basis, and all decisions by ALIEN shall be in its sole discretion with no obligation whatsoever. 
  

	5.5	If ALIEN timely indicates its desire to enter into negotiations for a license as set forth in Article 5.3, or if NDSU is free to exploit the invention as set forth in Article 5.4A.
or B., then ALIEN and NDSU shall enter into good faith license negotiations. Such good faith negotiations shall not exceed a negotiation period of four (4) months from receipt of the written notice required by Article 5.3 or from the expiration
of the response period set forth in Article 5.3. The negotiation period under this Article 5.5 may be extended upon mutual written agreement of ALIEN and NDSU. If ALIEN and NDSU cannot reach a mutually agreeable license, then either Party may
request non-binding mediation to assist the Parties to come to agreeable terms. 

  

	5.6	Subject to Article 2, for all inventions licensed exclusively to ALIEN under Article 5, NDSU shall: 

 A. retain a nonexclusive, nontransferable, nonsublicensable, fully paid up, royalty-free, license to make and/or use such inventions or practice such
patented processes for NDSU’s teaching and research purposes; and 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 8 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 B. retain a nonexclusive, nonsublicensable, fully paid up, royalty-free license to make for or sell
to the U.S. government such inventions for use by the U.S. government only; retain a nonexclusive, nonsublicensable, fully paid up, royalty-free license to have made for the U.S. government such inventions for use by the U.S. government only,
provided that ALIEN approves of the foundry in writing, in advance, with such approval not being unreasonably withheld nor delayed. 
  

	5.7	In the event that NDSU licenses inventions to third parties under this Article 5, the Parties shall equitably divide the compensation from such licensing activities. The equitable
division shall be negotiated in good faith by the Parties at the time of any contemplated license to a third party by NDSU. Such equitable division shall be determined in accordance with such appropriate relative values to patented inventions, in
proportion to the total value represented by all patented inventions and/or proprietary rights that are included within the third–party license. 

  

	5.8	ALIEN represents and warrants that it will retain all intellectual property rights necessary to perform, in good faith, its express obligations under this Agreement.

 ARTICLE 6 — PATENT PROSECUTION 
  

	6.1	The Parties shall, in their sole discretion, apply for, prosecute, and maintain all their own Solely Developed Intellectual Property arising out of or in connection with the
RESEARCH PROGRAM. 

  

	6.2	If the Parties create JOINTLY DEVELOPED INTELLECTUAL PROPERTY, the Parties agree to consult with one another as reasonably necessary to obtain and perfect intellectual property
rights specific to such technology. The Parties further agree to equitably share the cost of obtaining and perfecting such rights. In the event of a dispute, U.S. patent law shall govern. 

  

	6.3	In the event ALIEN elects an exclusive license under Article 5 of this Agreement, ALIEN shall reimburse all legal expenses, including Patent Cooperation Treaty (PCT) applications,
relating to patenting the intellectual property paid by NDSU and shall pay for all future expenses as long as ALIEN’s exclusive license to the intellectual property has not terminated. Nothing in this Article 6.3 shall be construed to
lessen NDSU’s management of the patent application, prosecution and maintenance of the intellectual property. ALIEN shall be consulted regarding the prosecution of such patents. ALIEN shall not be required to reimburse for PCT national phase
filings or foreign filings for any country unless such filings are at the request of ALIEN or NDSU secures ALIEN’s agreement prior to filing. 

  

	6.4	 As to patents prosecuted by NDSU for NDSU SOLELY DEVELOPED INTELLECTUAL PROPERTY on which ALIEN has elected to take an exclusive license under Article 5, NDSU shall
provide ALIEN with copies of all relevant documentation so that ALIEN may be informed and apprised of the continuing prosecution, and may provide substantive comment and input, and ALIEN shall keep this documentation 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 9 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	 
confidential in accordance with Article 2. NDSU shall endeavor to amend any patent application to include reasonable claims or disclosures requested by ALIEN
and required to protect the products and/or processes derived from the patent application. 

  

	6.5	As to patents prosecuted by either Party for JOINTLY DEVELOPED INTELLECTUAL PROPERTY, the prosecuting Party shall provide the other Party with copies of all relevant documentation
so that the other Party may be informed and apprised of the continuing prosecution, and may provide substantive comment and input, and the other Party shall keep this documentation confidential in accordance with Article 2. The prosecuting Party
shall endeavor to amend any patent application to include reasonable claims or disclosures requested by the other Party and required to protect the products and/or processes derived from the patent application. 

 ARTICLE 7 — INDEPENDENT CONTRACTOR 
 For purposes of
this Agreement, the Parties are independent contractors and not agents or employees of the other Party. No Party shall have the authority to make any statements, representations, or commitments of any kind, or to take any action that shall be
binding on the other Party, except as expressly provided in this Agreement. 
 ARTICLE 8 — PUBLICATION 
 A Party has the right to publish or otherwise publicly disclose information, other than the other Party’s trade secrets or CONFIDENTIAL INFORMATION, gained in the
course of or as follow-up to the RESEARCH PROGRAM. In order to avoid the disclosure of trade secrets or CONFIDENTIAL INFORMATION or the loss of patent rights as a result of premature public disclosure of patentable information, any prepublication
materials disclosing the other Party’s CONFIDENTIAL INFORMATION or information knowingly contained in patent applications shall be submitted by the publishing Party to the other Party whose technologies are described, for review and comment, at
least thirty (30) days prior to planned submission for publication. Such other Party shall notify the publishing Party within fourteen (14) days of receipt of such materials whether the materials contain any of its trade secrets or
CONFIDENTIAL INFORMATION subject to the Parties’ rights under Article 2. If such other Party notifies the publishing Party that the publication identifies/includes patentable material or trade secrets or CONFIDENTIAL INFORMATION, the
publishing Party shall withhold publication and disclosure of such materials until determination of patentability has been resolved or patent application(s) filed. In no event shall publication be delayed for a period exceeding six (6) months
from receipt of a request to delay publication. At DISCLOSING PARTY’s request, all DISCLOSING PARTY’s CONFIDENTIAL INFORMATION or trade secrets shall be removed by the RECEIVING PARTY from any publications or other disclosures. 

 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 10 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 ARTICLE 9 — PUBLICITY 
 Except as required by law or in the normal course of business identification, neither NDSU nor ALIEN shall issue any press release nor make any other written statements in connection with the RESEARCH PROGRAM intended
for use in the public media in a manner suggesting any endorsement by the other Party without approval of such other Party. Such approval shall not be unreasonably withheld or delayed. In any other statements, the Parties shall describe the scope
and nature of their participation accurately and appropriately. Notwithstanding anything to the contrary contained herein, the Parties agree that for press releases or other publicity that identifies DMEA or any DMEA contract included in the FULL
PROJECT SCOPE OF WORK, that such press release or publicity shall be submitted to DMEA for review and approval at least fourteen (14) days prior to such release. 
 ARTICLE 10 — EXPORT CONTROL COMPLIANCE 
 The Parties to this Agreement are subject to United States laws and
regulations controlling the export of technical data, computer software, laboratory prototypes, and other commodities, and agree to comply with applicable United States export laws and regulations. 
 ARTICLE 11 — MARKING 
 NDSU shall mark, or shall cause
to be marked, any products made or used pursuant to Article 4 with a notice that the product is “Licensed under one or more of U.S. Patent Nos. [such numbers to be provided to NDSU by Alien pursuant to Article 15]” and shall otherwise so
mark products in accordance with applicable patent laws and practices of the country in which the product is made or used. 
 ARTICLE 12
— DISPUTE RESOLUTION 
  

	12.1	The Parties wish to resolve efficiently disputes relating to or arising out of this Agreement. In the event of any dispute or perceived problem, the Parties shall attempt, in good
faith, to resolve the problem by negotiation within thirty (30) days of receipt of a request from the other Party. If negotiation is unsuccessful, the Parties shall, upon the request of either, attempt to settle the dispute by mediation within
the next thirty (30) days. The Parties shall mutually agree on the selection of the mediator(s). Each Party has the option to give notice to the other Party of its desire to seek first an amicable resolution without resort to litigation. Where
cure is possible, each Party shall be given sixty (60) days from the date of such notice to correct its performance under this Agreement or otherwise cure any breach. 

  

	12.2	 Excluding the provisions of Article 5.5, disputes not resolved pursuant to Article 12.1 shall be settled by mandatory arbitration upon request of either Party. Such
arbitration shall be conducted before a panel of three arbitrators appointed in accordance with the then-existing Commercial Rules of the American Arbitration Association. The arbitration hearing and the awards shall take place and be made within
ninety (90) days 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 11 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	 
of the filing of each initial demand for arbitration. Judgment upon the award of all or a majority of the arbitrators shall be binding upon the Parties and
may be entered in any court having jurisdiction. Venue for the arbitration shall be as determined by the panel. 

  

	12.3	Notwithstanding the foregoing, nothing in this Article shall be construed to waive any rights or timely performance of any obligations existing under this Agreement.

  

	12.4	Notwithstanding anything to the contrary, nothing in this Article shall be construed to limit a Party’s right to seek injunctive or other equitable relief in any court of
competent jurisdiction. 

 ARTICLE 13 — LIABILITY/WARRANTY 
  

	13.1	EXCEPT AS PROVIDED IN THIS ARTICLE 13, NO PARTY MAKES ANY WARRANTIES (EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE) WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT. CONFIDENTIAL
INFORMATION DELIVERED UNDER THIS AGREEMENT IS EXPERIMENTAL IN NATURE. THE PARTIES MAKE NO WARRANTIES OR REPRESENTATIONS WITH RESPECT TO ITS UTILITY, EFFICACY, NON-TOXICITY, SAFETY, OR APPROPRIATENESS FOR A PARTICULAR PURPOSE. ALL INFORMATION,
TECHNOLOGY, AND PRODUCT PROVIDED UNDER THIS AGREEMENT IS “AS IS.” 

  

	13.2	Each Party represents and warrants that (a) the execution, delivery, and performance of this Agreement by it is within its power and will not violate or conflict with, and is
not prohibited by, any law, regulation, certificate, agreement, or other instrument, rule, or order of which it is aware or to which it is bound; and (b) it has not and will not grant any rights that are inconsistent with the rights and
licenses granted to the other Party under this Agreement. 

  

	13.3	NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY, INDIRECT, CONSEQUENTIAL, EXEMPLARY, OR INCIDENTAL DAMAGES ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT OR THE SUBJECT
MATTER OF THIS AGREEMENT, WHETHER THE CLAIM IS BASED ON WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF THE PARTY IS ADVISED OF THE POSSIBILITY OF THE DAMAGES. THESE LIMITATIONS APPLY
NOTWITHSTANDING FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. 

  

	13.4	ALIEN represents and warrants that it, as of the EFFECTIVE DATE, owns or otherwise has the legal right to license or sublicense the LICENSED PATENTS as required under this
Agreement, and that it has received no notice of infringement or misappropriation of any rights in relation to the LICENSED PATENTS. NDSU represents and warrants that it will not knowingly exceed the scope of the license granted in Article 4.

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 12 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 ARTICLE 14 — TERM AND TERMINATION 
  

	14.1	Unless earlier terminated under a provision of this Article 14, this Agreement shall commence on the EFFECTIVE DATE and shall continue in full force and effect until April 30,
2005. The Agreement may be extended upon written agreement of the Parties. 

  

	14.2	Performance by the Parties under this agreement is dependent upon the appropriation of additional funds to NDSU from the United States government for the FULL PROJECT SCOPE OF WORK.
If the United States government fails to appropriate the additional funds to NDSU within a reasonable period of time, either Party may terminate this Agreement without further duty or obligation by providing written notice to the other Party of its
intent to terminate under this Article 14.2. NDSU shall notify ALIEN in writing as soon as reasonably possible after the unavailability of additional funds comes to NDSU’s attention. 

  

	14.3	If, after the awarding of the additional funds to NDSU from the United States government for additional phase(s) of the FULL PROJECT SCOPE OF WORK, the Parties then fail to reach
agreement on the subcontract(s) within sixty (60) days, either Party may then terminate this Agreement upon fourteen (14) days written notice to the other Party. The negotiation period for the subcontract(s) may be extended upon mutual
written agreement of ALIEN and NDSU. 

  

	14.4	In the event that one Party defaults on its material obligations under this Agreement and, if such default is capable of cure but the defaulting Party fails to remedy such default
within sixty (60) days after receipt of written notice thereof, the nondefaulting Party may terminate this Agreement at any time after the sixty (60) day cure period. 

  

	14.5	Termination or cancellation of this Agreement shall not affect the rights and obligations of the Parties accrued prior to termination. 

  

	14.6	Articles 3.3, 3.6, 5.6, 6, 11, 12, 13, 14.4, 14.5, 14.6, 14.7, 15, and 16 shall survive termination of this Agreement. Articles 2 and 8 shall survive termination of this Agreement
for a period of five (5) years. Articles 5.1, 5.2, 5.3, 5.4, 5.5, 5.7, and 5.8 shall survive termination of this Agreement for a period of three (3) years. The limited license granted in Article 4.1, but further limited to NDSU’s
right to make (but not have made) products or use processes under the LICENSED PATENTS for the sole purpose of research and development for the exclusive use of the U.S. government for U.S. government purposes, shall survive until the earlier of
(i) 15 years after termination of this Agreement, or (ii) the expiration, revocation, final declaration of unenforceability, final declaration of invalidity of the last remaining patent within the Licensed Patents. Notwithstanding the
foregoing, the license grant to NDSU under Article 4 shall immediately terminate if (a) NDSU breaches any express obligation to ALIEN for which there is no cure possible or timely performed or exceeds the scope of the present or surviving
license, as applicable, or (b) either Party terminates this Agreement under Article 14.2. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 13 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	14.7	It is further agreed that should ALIEN be adjudged bankrupt, become insolvent or enter into or make a composition with or assignment to its creditors, then and in such event, any
option to license or license from NDSU shall automatically terminate without notice, but such termination shall not impair any accrued rights of NDSU or relieve ALIEN from any other obligations of ALIEN arising upon such termination. In such event,
all rights of ALIEN to NDSU developed intellectual property shall revert back to NDSU. 

 ARTICLE 15 — NOTICE 

Any notice or other communication required or permitted to be given or made under this Agreement shall be in writing and delivered to the Party at its address
indicated below (or to such other address as a Party may specify by notice under this Article) by courier or by registered or certified airmail, postage prepaid, or by facsimile or electronic mail; provided, however, that all facsimile or electronic
mail notices shall be promptly confirmed within two business days of receipt by RECEIVING PARTY in the same fashion as notice was originated. All notices shall be effective as of the date received by the addressee at the address provided for the
addressee. 
 As to ALIEN Technology Corporation: 
 Paul Drzaic, Vice President 
 Alien Technology
Corporation 
 18220 Butterfield Blvd 
 Morgan Hill CA 95037 
 pdrzaic@alientechnology.com 
 Fax: (408) 782-3912 
 As to North Dakota State University: 
 Gregory J. McCarthy, Director 
 Center for
Nanoscale Science and Engineering 
 1735 NDSU Research Park Drive 
 Fargo, ND 58105-5756 
 Greg.McCarthy@ndsu.nodak.edu 
 Fax: (701) 231-8831 
 ARTICLE 16 — MISCELLANEOUS PROVISIONS 
  

	16.1	This Agreement will be binding on the successors and permitted assigns of the Parties. No failure or successive failures on the part of any Party, its successors or assigns, to
enforce any covenant or article, and no waiver or successive waivers on its or their part of any conditions of this Agreement shall operate as a discharge of such covenant, article, or condition, or render the same invalid, or impair the right of
the other Party, its successors and assigns, to enforce the same in the event of any subsequent breach or breaches by a Party, its successors or assigns. This Agreement may be executed in multiple original copies, each of which shall be deemed an
original and all of which taken together shall be one and the same Agreement. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 14 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	16.2	Whenever the context shall require, the singular shall include the plural, the plural shall include the singular and words of any gender shall be deemed to include words of any
other gender. 

  

	16.3	The headings and captions contained in this Agreement are inserted only as a matter of convenience and in no way define, limit, extend, or describe the scope of this Agreement or
the intent of any provisions. 

  

	16.4	In the event one or more of the provisions of this Agreement are declared invalid, illegal, or unenforceable in any respect under any statute, regulation, or law, whether state or
federal, such provision shall be fully severable and shall not affect any other provisions, and this Agreement shall be construed as if such invalid, illegal, or unenforceable provision had never been contained in this Agreement. The remaining
provisions of this Agreement shall remain in full force and effect and shall not be affected by the invalid, illegal or unenforceable provision or by its severance from this Agreement. The Parties shall negotiate in good faith to replace the invalid
provision with a provision that most closely reflects the original intent of the Parties. 

  

	16.5	No Implied Licenses. Nothing in this Agreement shall be construed as granting a Party, by implication, estoppel, or otherwise, any license or other right to any of the other
Party’s intellectual property other than the right(s) or license(s) that are expressly granted in this Agreement. 

  

	16.6	NDSU may, consistent with NDSU policy, assign ownership of its intellectual property to the NDSU Research Foundation (“Foundation”), provided, however, that prior to such
assignment Foundation agrees in a writing to NDSU, with ALIEN as a third party beneficiary, that Foundation shall comply with and assist NDSU in its compliance with the terms and conditions of this Agreement to the extent the terms and conditions
apply to the assigned intellectual property. In the event NDSU exercises such assignment, NDSU represents and warrants that the Foundation shall abide by the terms of Article 5.1 in the management of NDSU’s intellectual property.

  

	16.7	Other than the exception noted in 16.6, no Party shall assign this Agreement or any licenses granted under this Agreement without the prior written consent of the other Party.

  

	16.8	Except as to the United States government’s rights and as provided under Article 16.1 none of the provisions of this Agreement shall be for the benefit of, or enforceable
by, any third party. The terms of this Agreement are made for the sole benefit of the Parties and no other person or entity is intended to nor shall have any rights or benefits under this Agreement, whether as a third party beneficiary or otherwise.

  

	16.9	All remedies available to a Party for breach of this Agreement are cumulative and may be exercised concurrently or separately, and the exercise of any one remedy shall not be deemed
an election of such remedy to the exclusion of other remedies. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 15 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	16.10	This Agreement constitutes the entire agreement between the Parties as to licensing, technology transfer and intellectual property issues and supersedes all previous communications,
representations, agreements, or understandings relating to the subject matter of this Agreement, whether written or oral. This Agreement cannot be altered, amended, or modified except by a written instrument signed by the duly authorized
representatives of the Parties. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives who have the power to legally bind their respective Party. 
 APPROVED AND ACCEPTED 
  

									
	North Dakota State University	 		 	ALIEN Technology Corporation
					
	By:	 	 /S/    PHILIP
BOUDJOUK
	 		 	By:	 	 /S/    JEFF
JACOBSON

					
	Title:	 	Philip Boudjouk	 		 	Title:	 	Jeff Jacobson
		 	Vice President for Research,	 		 		 	President & CEO
		 	Creative Activities & Technology Transfer	 		 		 	
					
	Date:	 	June 20, 2002	 		 	Date:	 	June 17, 2002

  

									
	 APPROVED AS TO LEGAL FORM
AND SUFFICIENCY
	 		 	
					
	By:	 	 /S/    RICK JOHNSON
	 		 		 	
					
	Title:	 	Rick Johnson, J.D., LLM	 		 		 	
		 	NDSU General Counsel	 		 		 	
					
	Date:	 	June 15, 2002	 		 		 	

  

									
	 ACKNOWLEDGEMENT:
	 		 	
			
	I have read this Agreement. I understand, accept, and will abide by the terms and conditions of this Agreement.	 		 	
					
	By:	 	 /S/    GREGORY J.
MCCARTHY
	 		 		 	
					
	Title:	 	Dr. Gregory J. McCarthy	 		 		 	
		 	 Associate Vice President for
 Interdisciplinary
Research
	 		 		 	
					
	Date:	 	June 15, 2002	 		 		 	

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Page 16 of 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit A 
 Code descriptions 
 c=no government rights, g=government rights, a=allowed, p=provisional, cip=continuation in part, cXX
continuation + priority date, pct=foreign filing under patent convention treaty 
  

							
	Issued Patents
	5,545,291	  	Smith, Yeh (R. Ogawa-g)	  	12/17/93	  	Method for Fabricating Self-assembling Microstructures
	P-023	  	Description: A method for assembling microstructures onto a substrate through fluid transport. The microstructures are shaped blocks self-aligned into recessed regions located
on a substrate such that the microstructure becomes integral with the substrate.
	5,783,856	  	Smith, Yeh (R. Ogawa-g)	  	5/9/95	  	Method for Fabricating Self-assembling Microstructures
	P-024	  	Description: A microstructure including a substrate with recessed tapered regions and shaped blocks in recessed regions.
	5,824,186	  	Smith, Yeh (R. Ogawa-g)	  	6/7/95cip	  	Method... for Fabricating Self-assembling Microstructures
	P-025	  	Description: FSA with “shaped blocks” including “plastic sheets forming active LCDs and the like”.
	5,904,545	  	Smith, Yeh, Hadley, Vermal (R. Ogawa-g)	  	6/7/95	  	Method for Fabricating Self-assembling Microstructures
	P-026	  	Description: A method for assembling microstructures onto a substrate through fluid transport. The microstructures are shaped blocks self-aligned into recessed regions located
on a substrate such that the microstructure becomes integral with the substrate.
	6,281,038	  	Jacobsen, Hadley, Craig (J. Scheller-g)	  	3/16/99	  	“Apparatus & Method for Forming Assemblies”
	P-016	  	Description: Eliminating tilted blocks by pressing them into the holes.
	6,274,508	  	Jacobsen, Gengel, Smith (J. Scheller-c)	  	3/16/99	  	“Apparatus & Method for Forming Assemblies”
	P-011	  	Description: Method of embossing receptor holes.
	6,291,896	  	S. Smith (J. Go-c)	  	2/16/99	  	“Functionally Symmetric integrated Circuit Die”
	B1, P001	  	Description: IC chips which are both physically and functionally symmetrical but where these forms of symmetry may be different - for example a physically 2-way symmetrical
NanoBlockTM IC with 4-way functional symmetry.
	6,316,278	  	Jacobsen, Gengel, Craig (J. Scheller-c)	  	3/16/99	  	“Method & Apparatus for Fabricating a Multi Modular Assembly”
	P-010	  	Description: Displays, antenna and other devices are fabricated as laminations of multiple rigid or flexible films — including driver backplane, finely patterned
interconnect layers, and coarsely patterned interconnect layers.
	6,380,729	  	S. Smith (J. Go-c95)	  	2/16/99a	  	“Testing Integrated Circuit Die”
	P-006	  	Description: Methods for testing the Nanoblocks before they are separated including ways to separate defective Nanoblocks from functional Nanoblocks. The IC die are
temporarily coupled together with a metal strap - a “switchable coupling” -- for testing and then separated as part of the die separation etch.
	Patents Pending
	P-002	  	S. Smith (J. Go-c95)	  	2/16/99	  	“Pixel Integrated Circuit”
		  	 Description: Circuit description of the Telcom and Quartz class of NanoBlockTM ICs.
 B-Priority/Display/USA only

	P-003	  	Smith, Hadley, Craig, Nealey (J. Scheller-g)	  	11/2/99	  	“Methods for improved flow in performing fluidic self assembly”
		  	Description: The correct selection of surface chemistry and FSA fluid reduces the amount of friction between the Nanoblocks and the substrate, thereby increasing both the
speed and yield of the FSA process.
	P-004	  	Smith, Hadley, Tu (J. Scheller-c95)	  	11/2/99	  	“Methods for Creating Elements of Predetermined Shape ...”
		  	Description: Process for making NanoBlock ICs.
	P-005	  	Smith, Hadley, Craig, Lowe (J. Scheller-g)	  	11/2/99	  	“Methods for forming openings and ... for creating assemblies ...”
		  	Description: Describes methods for making recessed tapered holes in various substrates and optimum hole shapes.
	P-007	  	Smith, Hadley, Craig, Lowe (J. Scheller-g)	  	11/2/99	  	“Methods and Apparatuses for Fluidic Self Assembly”
		  	Description: Describes use of helper blocks, vibration, nozzles, and evaporation triggered bonding to improve FSATM process.
	P-008	  	Jacobsen, Smith, Hadley (J. Scheller-c99)	  	2/5/99a	  	“Apparatuses and Methods for Forming Assemblies”
	P-008.1	  	Description: Describes web fabrication of FSATM devices.
	P-009	  	Jacobsen, Hadley, Smith (J. Scheller-g)	  	3/16/99a	  	“Methods for Transferring Elements from a Template ...”
		  	Description: xxx.
	P-012	  	Jacobsen, Gengel, Hadley, Craig, Smith (J. Scheller-c)	  	3/16/99	  	“Web Process Interconnect in Electronic Assemblies”
		  	Description: Displays, antennas and other devices consist of backplanes interconnected with flexible films.
	P-014	  	Jacobsen, Stewart (c)	  	8/17/01	  	“Apparatus & Method for Forming Electronic Assemblies”
		  	Description: 4-lead serial interface with multifunction leads. (First material received Oct ‘98, supplemented with RGS multi-function leads in 1999)
	[***]	  		  		  	
	P-018	  	Boling, Jacobsen, Nowicki (c)	  	8/17/01	  	“Apparatus & Method for Forming Electronic Assemblies”
		  	Description: FED, plasma and other displays driven with FSA backplanes with level shifters.
	P-021	  	Hadley, Chiang, Craig, Jacobsen, Smith, Tu, Stewart (c95)	  	11/27/00	  	“Web Fabrication of Devices”
		  	Description: Includes FSA of 2 or more sizes of Nanoblocks either sequentially or simultaneously. Also describes template transfer of multiple Nanoblocks.
	P-027	  	G. Gengel (c)	  	4/2/01	  	“Integrated Circuit Packages Assembled Utilizing FSA”
		  	 Description: General purpose packaging with FSA. 
 Current Claim #

	P-028	  	Stewart, Boling, Jacobsen (g)	  	9/27/00pct	  	“Display Devices and Integrated Circuits”
		  	Description: Covers the design of the Zircon “smart” Nanoblock.
	P-030	  	Smith, Yeh (R. Ogawa-g)	  	12/17/93cip	  	“Method for Fabricating Self-assembling Microstructures”
		  	Description: Continuation in part of 5,545,291. Includes a structural claim to the NanoBlockTM. IC itself without the substrate or other elements. May also cover
NanoBlockTM LEDs or other light emissive devices.
	P-034	  	J. Bernkoph (g)	  	12/6/01	  	“Split-Fabrication for Light Emitting Display Structures”
		  	Description: An active matrix backplane is laminated to a matrix of OLEDs. The OLED structure is protected during lamination by barrier layer and electrical connection is made
through a deformable conductor.
	P-035	  	Credelle, Gengel, Stewart, Joseph (c)	  	5/31/01	  	“Electronic Structures Having Multi-Density Components”
		  	Description: Interposers like RFID “Smartstraps” and display “Patches” are used to connect expensive high-density IC chips to low-cost low-density
substrates in a cost-efficient manner.
	P-039	  	Stewart, Smith (J. Scheller-c)	  	5/31/01	  	“Methods and Apparatuses to Identify Devices”
		  	Description: A fast bi-directional anti-collision binary search protocol requires only 2-state replies from the reader.
	P-041	  	Hermanns, Eisenhardt, Gengel (c)	  	4/25/01	  	“Contacts for Flexible Devices”
		  	Description: Flexible substrates with backside contacts.
	P-048	  	Snyder, Craig, Tu (g)	  	7/13/01p	  	“FSA & Asymmetric Blocks”
		  	Description: IC chips of different handedness and asymmetry are used to increase FSATM and silicon efficiency.
	[***]	  		  		  	
	P-051	  	S. Smith (c)	  	—	  	“Tag Search with 1 & Zero Bar”
		  	Description: xx.
	P-056	  	Gengel, Hadley, Eisenhardt, Hemmingway (c)	  	—	  	“Low-Cost RFID Conductive Adhesive”
		  	Description: Hybrid thin film/thick film tag structure.
	P-057	  	Carrender, Price, Nylander, Rolin, Stewart (c)	  	10/9/01p	  	“Methods and Apparatus for Identification”
		  	Description: Byte-wide anti-collision search protocol & reader-to-reader anti-collision.
	P-200	  	Stewart, Stewart (c)	  	5/31/01	  	“Compressed Tag Codes & Mapping”
		  	Description: Circuit and mapper for compressing 96-bit field codes into efficient 64-bit tag codes.
	P-201	  	Stewart, Rolin (c)	  	5/31/01	  	“Persistent Data Storage”
		  	Description: The state of key IC nodes is stored for extended periods even if the chip loses power during this time.
	P-202	  	Stewart, Rolin, (Smith) (c)	  	5/31/01	  	“Phase Channelization”
		  	Description: 8 tags are addressed concurrently via separate phase channels.
	P-203	  	Stewart Rolin, Carrender (c)	  	5/31/01	  	“Destruct Sequence”
		  	Description: A destruct sequence is used to protect privacy by permanently destroying tags in a controlled manner that prevents unauthorized destruction of tags by a
thief.
	[***]	  		  		  	

							
	Patents Applications in Progress
	[***]	  		  		  	
	P-036	  	Hartley, Eisenhardt (c)	  	—	  	“Double-Metal Background Driven Displays’’
		  	Description: The web substrate is interconnected with a metal layer under the Nanoblocks.
	[***]	  		  		  	
	P-047	  	Vincentini, Credelle (c)	  	—	  	“Array Strip Drivers”
		  	Description: Displays or sensor arrays driven by multiple Nanoblocks formed as either a monolithic substrate or multiple Nanostrips connected together.
	P-050	  	K. Schatz (c)	  	—	  	“Field Assisted FSA”
		  	Description: Electric fields are used to accelerate FSA process.
	[***]	  		  		  	
	P-053	  	Credelle, Alvarado (c)	  	—	  	“Pick & Place with Micro FSA”
		  	Description: FSA occurs in localized water droplets and is used to improve FSA alignment accuracy.
	P-055	  	S. Herrmann (c)	  	—	  	“Layout with Barrier Film & Block”
		  	Description: Previously preferred sealing structure for NanoBlockTM IC backplane driven OLED displays.
	[***]	  		  		  	

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 17 of 17IC Technology Development Agreement

 Exhibit 10.31 
 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
 IC TECHNOLOGY DEVELOPMENT AGREEMENT

 This IC TECHNOLOGY DEVELOPMENT AGREEMENT (the “Agreement”) is entered into effective as of 27 of May 2005 (the
“Effective Date”), by and between Tower Semiconductor Ltd., an Israeli company with principal offices located at Ramat Gavriel Industry Zone, Migdal Haemek, 23105 Israel, (“Tower”) and Alien Technology Corporation, a Delaware
corporation with principal offices located at 18220 Butterfield Blvd, Morgan Hill, California 95037, USA (“Alien”). 
 RECITALS

 WHEREAS, Alien is designing and selling RFID tags that include integrated circuits and wishes to engage Tower to provide services
relating to the design of certain integrated circuits and the development of associated process technology; and 
 WHEREAS, Tower is willing
to provide, on the terms and conditions set forth in this Agreement, the design and process development services for integrated circuits, as described in the applicable Statement of Work and any exhibits attached thereto. 
 WHEREAS, Alien and Tower signed on September 3, 2004 a letter agreement titled “Memorandum of Understanding/Preliminary Agreement” (the
“MOU”) with respect to the design and process development of an IC and have commenced work under the MOU. 
 WHEREAS, Alien and
Virage Logic have an agreement dated September 24, 2004 for the development of embedded module of electrically programmable non volatile memory optimized for RFID IC application to be manufactured using Tower’s manufacturing process (“Base
RFID NOVeA”) to be embedded in Alien’s RFID IC to be manufactured at Tower. 
 AGREEMENT 
 NOW, THEREFORE, for good and valuable consideration, the parties hereto agree as follows: 
 1. DEFINITIONS. Unless this Agreement expressly provides otherwise, the following terms shall have the meanings set forth below: 
 1.1 Technology means inventions, trade secrets, know-how, designs, information, data, processes, methods, techniques, drawings,
component board models, layouts, schematics, diagrams, functional blocks, Circuits, Devices, cells, design tools, software, design rules, simulation models, net lists, software, test protocols, test structures, characterization and test results,
methods and patterns, specifications and other technical information, whether or not patentable or otherwise protectable. 
 1.2 Process means, with respect to the Technology, recipes, modules and other items of semiconductor manufacturing process Technology used to fabricate integrated circuits and other semiconductor devices and products, including
variants of such Technology and any improvements, updates or revisions thereto. The Tower Process Technology in use for any given Statement of Work will be described in such Statement of Work. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 1.3 Assembly means, with respect to a Technology, the manufacturing steps used
to integrate discrete integrated circuits into a stand-alone electronic system. 
 1.4 Circuit means a unit, comprised
of two or more active and/or passive Devices interconnected with each other and imprinted or associated on one or no re silicon substrates that is forming or performing a defined electrical function. 
 1.5 Device means an element (such as a transistor, diode, resistor, capacitor or inductor) that performs a specific electrical
function, excluding Circuit. 
 1.6 Existing means, with respect to a Technology or Intellectual Property Rights, the
Technology or Intellectual Property Rights owned or used, initially as of the Effective Date and thereafter as at the effective date of each SOW, by a party and which such party may use or provide to the other party in the performance of work under
this Agreement. 
 1.7 Developed means, with respect to a Technology or Intellectual Property Rights, all inventions,
discoveries, improvements and modifications to a Technology or Intellectual Property Rights developed during the course of work under a SOW. 
 1.8 Jointly Owned Developed Technology (JODT) means any Developed Technology that is jointly owned by the parties pursuant to Sections 6.4(b) and 6.4(e) of this Agreement. JODT shall expressly exclude any
underlying Existing Technology and Existing Intellectual Property Rights. 
 1.9 IC means an integrated circuit.

 1.10 RFID IC means integrated circuits that are incorporated into Radio Frequency Identification (“RFID”)
tags. 
 1.11 Intellectual Property Rights (IPR) means any and all copyrights, trade secret rights, inventions, patent
rights, design rights, database rights, mask works, topography rights and know-how, whether registered or unregistered, and including any application for registration for any of the foregoing, and any rights of similar nature or effect existing
anywhere in the world. 
 1.12 Statement of Work (SOW) means each separate statements of work to be mutually agreed
upon by Alien and Tower from time to time describing specific development projects to be conducted under this Agreement, and the parties respective responsibilities therein, as such projects are agreed by the parties to be undertaken. 
 1.13 Services mean the projects, tasks, services, and other work as described in and carried out by Tower under this Agreement or a
SOW. 
 1.14 Confidential Information means any information disclosed by one party to the other in connection with the
performance of this Agreement, including Technology and other information that relates to the disclosing party’s products, designs, business plans, business 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 2 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
opportunities, finances, research, development, know-how, personnel, or third-party confidential information disclosed to the receiving party by the
disclosing party in any form whatsoever (including, but limited to, disclosure made in writing, orally or in the form of samples, models, computer programs or otherwise), and the terms and conditions of this Agreement, provided that such information
is at the time of disclosure designated as “confidential” or the nature of the information makes it obvious that it is confidential. Confidential Information does and will not include material that: 
 (a) is now or subsequently becomes generally available to the public or is disclosed to third parties without restriction on its use or
disclosure, provided that an officer of the disclosing party with the authority to determine that such information should not be treated as confidential authorized such general availability or disclosure; 
 (b) the receiving party can demonstrate that it had rightfully in its possession prior to disclosure by the disclosing party; 

(c) is developed independently by or for the receiving party without the use of any Confidential Information of the disclosing party or
otherwise in breach of this Agreement; 
 (d) the receiving party rightfully obtains without restriction from a third party
who has the right to transfer or disclose it and is not in breach of a confidentiality agreement with the disclosing party; or 
 (e) is disclosed without restriction on further disclosure, as expressly indicated in writing by ail officer of the disclosing party with authority to make such a determination. 
 1.15 Residual Information means information that is retained in the unaided memories of the receiving party’s employees who
lawfully have had access to the disclosing party’s Confidential Information pursuant to the terms of this Agreement and that employee’s specific responsibilities. An employee’s memory is unaided if the employee has not intentionally
memorized the information for the purpose of retaining and subsequently using or disclosing it, and has not recorded the information. 
 1.16 Exclusivity Period [***]. The Exclusivity Period is subject to extension commensurate with any material delays caused by Tower or [***], including without limitation delays in the wafer manufacturing
process and delays resulting from revised versions of such deliverables necessitated by problems in the initial deliverables by reason of the fault of Tower or [***] and without substantial contributing fault of Alien. 
 2. SCOPE OF SERVICES 
 2.1 Cooperation. During the term of this Agreement, the parties will work together in a mutually beneficial and cooperative fashion as set forth in executed SOWS in order to 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 3 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
develop RFID IC products, related Process Technologies, including Process Technology modules specifically designed for RFID IC, and to create mutually
beneficial technological solutions. 
 2.2 Statements of Work. Each joint development project undertaken by the parties
will be covered by a separate Statement of Work which: 
 (a) shall be in substantially the form attached hereto as
Exhibit A; 
 (b) shall be subject to the terms and conditions of this Agreement; 
 (c) shall set forth in reasonable detail: (i) a description of the project, the Services to be performed by Tower, the work to be
performed by Alien and any additional work or tasks to be performed by third parties; (ii) each party’s contributions of employee, engineering and design resources, equipment, supplies, capital, and Existing Technology and Intellectual
Property Rights; (iii) the items to be delivered by Alien to Tower under the SOW (“Alien Deliverables”), the items to be delivered by Tower to Alien in connection with the Services (“Tower Deliverables”), and the items, if
any, to be delivered to either Alien or Tower by third parties (“Third Party Deliverables”), including the hardware and software, reference designs, technical papers, prototypes and other work product to be generated from the Services;
(iv) the development schedule; (v) key milestones for the Services; (vi) the roles and responsibilities of each of the parties, and of third parties, in completing the development, including in the evaluation, characterization,
testing and debugging of prototypes; (vii) if applicable, the roles and responsibilities of the parties in manufacturing, marketing, promotion, advertisement, commercialization, distribution and sale of products created under or resulting from
the Services or otherwise under the SOW; 
 (d) shall specify payments to be made by Alien to Tower for the performance of
Services and any other payments the parties agree to with respect to the project covered by the SOW; 
 (e) may contain
additional terms and conditions, including terms expressly modifying the terms of this Agreement, which for purposes of such Statement of Work supersede any conflicting provisions set forth in this Agreement, without modifying: (i) any
provision of this Agreement not expressly modified in such Statement of Work; or (ii) with respect to any other Statement of Work, those or any other provisions of this Agreement. 
 2.3 Obligation to Perform. Subject to Alien’s agreement to make payments as set forth in Section 5 and the applicable
Statement of Work, Tower agrees to engage in performance of Services for Alien. Tower shall have no obligation to commence Services until the applicable Statement of Work is agreed upon and fully executed. Alien shall have no obligation to commence
performance under a SOW until the SOW is agreed upon and fully executed. 
 2.4 Timing and Disclosures. Each party
agrees to use commercially reasonable efforts to perform its responsibilities, if any, as set forth under each applicable SOW and to allocate sufficient resources to complete the Services and other tasks in accordance with the relevant 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 4 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
specifications and development schedule set forth in such SOW. In the event resource constraints are preventing a timely completion of Services or other
tasks under a SOW, each party will make commercially reasonable efforts to address the constraints to ensure completion of the project within the project timeline. To the extent permitted under its existing contractual obligations, each party, in
its discretion, will disclose to the other Confidential Information that is relevant to the other in performing the Services and other work under a SOW, including its relevant Existing Technology necessary to complete the SOW. While the parties
intend to disclose to one another Confidential Information including their relevant Existing Technology as part of any projects undertaken under this Agreement, for avoidance of doubt, neither party is to have an affirmative obligation hereunder to
assist in show-how, or the teaching of or transfer of know-how ill its Existing Technology or Developed Technology to the other party. 
 2.5 Change Orders. Either party may propose changes or modifications to a SOW. Both Parties will timely review ally proposed changes to a SOW and will identify impacts of such changes 011 the development
schedule, cost and deliverables under the SOW. Any modification or amendment to a Statement of Work agreed by the parties shall take effect by executing a written Change Order in substantially the form attached hereto as Exhibit B. Each
Statement of Work will be deemed to include all executed Change Orders that reference and modify such Statement of Work. Until such time as any Change Order is fully executed by both parties, Tower will continue to perform and be paid for the
Services as if such change had not been requested. 
 2.6 Purchase Order Terms Superseded. The terms and conditions of
this Agreement and the related Statements of Work and Change Orders shall exclusively govern all terms of the projects undertaken under this Agreement, including the performance of any Services and the provision of any Tower Deliverables to Alien,
and shall supersede all terms and conditions contained in any purchase order, order, order acknowledgement form, invoice or other business form submitted by either party to the other with respect to the subject matter of this Agreement and any SOW.

 2.7 Framework Agreement. This Agreement shall serve as an overall framework with respect to the joint Technology
developments of the parties, and it contains general principles regarding the parties’ responsibilities, cost sharing and ownership and use of Intellectual Property Rights and Developed Technology applicable to all projects undertaken under a
SOW executed by the parties, which principles may be modified on a project-by-project basis in the SOW as contemplated in Section 2.2(e), provided such modifications are signed by both Parties. 
 3. RELATIONSHIP OF THE PARTIES 
 3.1 Independent Contractors; No Joint Venture. The parties acknowledge their relationship is that of independent contractors. Nothing in this Agreement shall be construed to create a joint venture, partnership,
employment or agency relationship between Alien and Tower or Tower’s employees or contractors. Neither party is authorized to represent, bind, obligate or contract on behalf of the other. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 5 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 3.2 Subcontractors. Tower may use Tower Semiconductor U SA, Inc. (“Tower
USA”) and the subcontractors listed on Exhibit C (the “Approved Subcontractors”) to perform the Services or any part thereof, provided that such use shall not relieve Tower of its obligations under this Agreement or any SOW, and
Tower shall be responsible for ensuring that the Approved Subcontractors comply with the provisions hereof and of any applicable SOW. Additional subcontractors may be added to Exhibit C with Alien’s prior written approval, which will not be
unreasonably withheld or delayed. It being agreed that if Alien does not respond with its approval or disapproval of any requested addition within fourteen days after receiving the request for approval, Alien will be deemed to have approved such
addition. 
 3.3 Other Customers and Projects. 
 (a) Subject to the terms of this Agreement (including without limitation Section 3.3(b) and the restrictions on use and disclosure of
Confidential Information in Section 8), Tower shall be free to engage in other work, alone or with others, and to furnish information to and receive information from others, both during and after the term of this Agreement. 
 (b) [***]. 
 (c) Subject to the restrictions on use of Technologies and disclosure of Confidential Information as set forth in Sections 6, 7 and 8, Alien may collaborate with, or enter into a development agreement with a third party, before, during or
after the term of a project under this Agreement which is in the same subject area as any particular project contemplated by this Agreement. 
 4. RESPONSIBILITIES 
 4.1 Alien’s Responsibilities. 
 (a) With respect to each SOW, Alien agrees to designate (i) a project manager or single point of contact for Tower for the duration
of the Services to be performed under such SOW and (ii) all executive to whom issues unresolved between the parties’ project managers can be escalated for attempted resolution. 
 (b) Alien is responsible for the accuracy, completeness and quality of information or other materials supplied by Alien and used in
preparation of a SOW or in performance of the Services. 
 (c) Alien shall dedicate appropriate staff to each development
project, as specified in the applicable SOW. 
 (d) Alien shall provide Tower with reasonable access to Alien’s
facilities, subject lo Alien’s standard rules and regulations for such facilities, at all reasonable times when necessary to perform the Services. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 6 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (e) Alien understands that in order to be able to fully use the results of the
Services performed hereunder, it may be necessary for it to obtain licenses from third parties (such as vendors of physical libraries and other intellectual Property components). 
 (f) Alien acknowledges that Tower’s ability to perform in its obligations (which may include delivery schedules) as set forth in this
Agreement or any SOW is contingent upon Tower receiving timely, accurate and completed data, information, assistance and specifications from Alien and, in certain cases, from third parties. Alien shall promptly notify Tower of anticipated delays in
the delivery of items, which are Alien’s responsibility and shall provide prompt assistance in resolving any such delays or any defects in such items reported by Tower. 
 4.2 Tower’s Responsibilities. 
 (a) With respect to each SOW, Tower agrees to designate (i) a project manager or single point of contact for Alien for the duration of the Services to be performed under such SOW and (ii) a11 executive to
whom issues unresolved between the parties’ project managers can be escalated for attempted resolution. 
 (b) Tower is
responsible for the accuracy, completeness and quality of information supplied by Tower and used in preparation of the SOW or in performance of the Services. 
 (c) Tower shall dedicate appropriate staff to perform the Services described in the applicable SOW. 
 (d) Tower shall provide Alien with reasonable access to Tower’s facilities, subject to Tower’s standard rules and regulations
for such facilities, at all reasonable times when necessary to assist in performance of the Services or other tasks to be performed by Alien as set forth in the applicable SOW. 
 (e) Tower shall promptly notify Alien of anticipated delays in the delivery of items, which are Tower’s responsibility and shall
provide prompt assistance in resolving any such delays. 
 5. BILLING AND PAYMENT 
 5.1 Interim Payments. A SOW may provide for certain payments to be made following the passage of certain dates “Interim
Payment”). Following the passage of each such date (each an “Interim Date”), Tower shall invoice Alien for the applicable amount, it being understood that the date of Towel’s invoice shall not be earlier than the applicable
interim Date. Each Interim Payment shall be due and payable thirty (30) days after the date of invoice. 
 5.2 Milestone
Payments. A SOW may provide for certain portions of the Services to be completed by interim deadlines (“Milestones”), achievement of which by Tower will trigger Tower’s right to invoice Alien for, and Alien’s obligation to
pay, the associated payment (“Milestone 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 7 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
Payment”). Tower will use commercially reasonable efforts to achieve all Milestones and upon successful completion of a Milestone, Tower will provide to
Alien a statement describing such achievement along with an invoice for the amount of the applicable Milestone Payment. The date of each such invoice shall not be earlier than the date that Tower achieves the applicable Milestone (the
“Milestone Date”). Each Milestone Payment shall be due and payable thirty (30) days after the date of invoice. 
 5.3 Wafer and Mask Payments. A SOW (including by way of incorporating a price quotation submitted by Tower to Alien and signed by Alien) may provide for certain payments to be made to Tower in connection with the manufacturing of
wafers and the making of masks. Tower will invoice Alien for payments associated with wafer manufacturing and mask malting. Wafer manufacturing related payments will be due and payable thirty (30) days after the date of invoice. If so set forth on
the applicable invoice, mask making related payments will be due fourteen (14) days after the date of invoice. It is understood that the date of each such invoice will not be earlier than (a) in the case of masks, receipt of the applicable
GDSII file at Tower, and (b) in the case of wafers, the date of shipment of the applicable wafers to Alien. 
 5.4
Taxes. The amounts payable to Tower under this Agreement do not include any sales, use or other governmental taxes or charges. Alien agrees to pay all applicable taxes, duties or governmental charges (other than taxes based on Tower’s
net income), regardless of when they may come due, or to reimburse Tower for the same if Tower is required by applicable law to collect and pay over the same to the relevant taxing authority. 
 5.5 Late Payments. If Alien Fails to make payments when due, and such payments are not the subject of a good faith dispute, Tower
may charge Alien interest on the overdue amount from the date such amount became due at the lesser of 1% per month or the maximum interest rate permitted by applicable law. In addition, Alien will be liable to Tower for all costs of collection
incurred by Tower in collecting past clue amounts. Nothing in this section shall limit any other remedies available to Tower. 
 6.
INTELLECTUAL PROPERTY RIGHTS 
 6.1 Existing Technology. The parties agree that as between Tower and Alien,
unless otherwise provided in a SOW: (i) Existing Technology of Alien and all Intellectual Property Rights therein are and shall be owned by, and shall remain the sole and exclusive property of Alien; and (ii) Existing Technology of Tower
and all Intellectual Property Rights therein are and shall be owned by, and shall remain the sole and exclusive property of Tower. Except as arid to the extent otherwise provided in this Agreement or an applicable SOW, neither this Agreement nor the
performance of Services hereunder shall give either Tower or Alien any ownership interest in or right to any Existing Technology or Existing Intellectual Property Rights held by the other party. 
 6.2 Developed Process Technology and Devices. The parties agree that as between Tower and Alien, unless otherwise provided in a
SOW, all Developed Process Technology, Developed Devices (and all Intellectual Property Rights therein) arising from work carried out under 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 8 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
a SOW, including any and all Developed Process Technology modules and Developed Devices specifically designed for the manufacturing of RFID IC, shall be the
exclusive property of Tower, regardless of whether such Developed Process Technology and Developed Devices are invented solely by Tower, solely by Alien or jointly by the parties. Tower shall be free to use any Developed Process Technology and
Developed Devices or any other improved Process Technology or Devices arising eon? development projects or developed independently from a SOW to offer foundry services to any entity, including Alien. Tower shall have the sole and exclusive right
(but not the obligation) to seek patent protection (or any other form of Intellectual Property Rights) covering any Developed Process Technology and Developed Devices iii all countries of the world at its sole expense and shall have full control
over the prosecution and maintenance of such patents or other Intellectual Property Rights and title to any patent or other Intellectual Property Rights issuing therefrom shall be issued solely in the Tower’s name. 
 6.3 Developed Assembly Technology and Developed Circuits. The parties agree that as between Tower and Alien, unless otherwise
provided in a SOW, all Developed Assembly Technology and Developed Circuits (and all Intellectual Property Rights therein) arising from Work carried out under a SOW, including ally and all Developed Assembly Technology modules and Developed Circuits
specifically designed for Alien under SOWS pursuant to this Agreement, shall be the exclusive property of Alien, regardless of whether such Developed Assembly or Developed Circuits Technology are invented solely by Tower, solely by Alien or jointly
by the parties. Alien shall be free to use any Developed Assembly Technology and Developed Circuits or any other improved Assembly Technology and Developed Circuits arising from development projects or developed independently from a SOW to design,
manufacture and assemble Alien products wherever manufactured. Alien shall have the sole and exclusive right (but not the obligation) to seek patent protection (or any other form of Intellectual Property Rights) covering any Developed Assembly
Technology and Developed Circuits in all countries of the world at its sole expense and shall have full control over the prosecution and maintenance of such patents or other Intellectual Property Rights and title to any patent or other Intellectual
Property Rights issuing therefrom shall be issued solely in the Alien’s name. 
 6.4 Other Developed Technology.
Except in the areas of Process, Assembly, Device and Circuit (the rules for which are set forth in Sections 6.2 and 6.3 above), the parties agree that as between Tower and Alien, unless otherwise provided in a SOW, the following rules shall apply in
the following descending order to determine the ownership of items and deliverables of other Developed Technology (and all Intellectual Property Rights therein), arising from work carried out under a SOW: 
 (a) Any item identified to be owned by a particular party in the applicable SOW, shall be exclusively owned by such party. 
 (b) Any item expressly identified to be Jointly Owned Developed Technology by the parties in the applicable SOW shall be jointly owned in
equal undivided interests by Tower and Alien (unless a different joint ownership arrangement expressly described in the applicable SOW). 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 9 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) Any item that has been primarily derived from an Existing Technology or
Intellectual Property Rights of a party shall be exclusively owned by such party. 
 (d) Any item that has been primarily
developed by a party shall be exclusively owned by such party, notwithstanding any inputs and suggestions that the other party may have made in regard to such work and deliverables. 
 (e) Any item developed or reduced to practice jointly by the parties during the course of the performance of a SOW not covered by
sub-Sections 6.4 (a) through (d) above shall be Jointly Owned Developed Technology, owned in equal undivided interests by Tower and Alien. 
 6.5 Assignment of Rights. Except for items of Jointly Owned Developed Technology, the party that is not entitled to own an item pursuant to the rules set forth in Sections 6.2, 6.3 and 6.4 of this Agreement,
hereby assigns to the owning party all right, title and interest it may have in such item and any Intellectual Property Rights therein. The owning party shall have the sole and exclusive right (but not the obligation) to seek patent protection (or
other Intellectual Property Rights) covering any item it solely owns in all countries of the world, at its sole expense, and shall have full control over the prosecution and maintenance of such patents (or other Intellectual Property Rights) and
title to any patent (or other Intellectual Property Rights) issuing therefrom shall be issues solely in the name of the owning party. 
 6.6 Jointly Owned Developed Technology. Tower and Alien shall: 
 (a) execute any and
all documents necessary to effectuate their equal and undivided interests to Jointly Owned Developed Technology; 
 (b) have
the right to freely use, exploit, protect, maintain, license, transfer and enforce its rights to the portion of any Jointly Owned Developed Technology that is not Existing Technology with no royalty payment or accounting to the other party, provided
each party shall bear its portion of Joint Costs (as defined below); and 
 (c) jointly share expenses incurred in securing
rights mutually agreed to be prosecuted by the parties such as those associated with obtaining and maintaining Intellectual Property Rights with respect to Jointly Owned Developed Technology (“Joint Costs”). If one party elects not to seek
or secure such rights on Jointly Owned Developed Technology in any particular country or not to share equally in the expenses thereof, the other party will have the right to seek and maintain such protection at its own expense and shall have full
and exclusive control over the prosecution and maintenance thereof, even though title to any Intellectual Property Rights arising from Jointly Owned Developed Technology will be joint; provided, however, that the non-participating party agrees that
it will not have the right to grant licenses under such Intellectual Property Rights to third parties (other than its own majority-owned subsidiaries) in such country or countries. Each party hereby forever waives and releases any right it has or
will have in the future to require any accounting, sharing or payment of profits from the other in connection with Jointly Owned Developed Technology. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 10 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 6.7 Cooperation and Disclosure. Tower and Alien will: 
 (a) perform such acts, execute and deliver such instruments and documents, submit such filings, and do all such other things as may be
reasonably necessary to evidence, perfect and enforce the rights of the parties stated in this Section 6; 
 (b) cause
their employees performing work under this Agreement or an applicable SOW, whether solely or jointly with others, to promptly make a complete written disclosure to their employer for patent review of any Developed Technology, the normal course,
specifically pointing out those features or concepts believed to be new or different; and 
 (c) promptly submit to the other
party copies, marked as Confidential Information, of any written disclosures pertaining to Developed Technology which is deemed to be owned by the other party or deemed to be Jointly Owned Developed Technology under this Agreement, including any
filing or receiving of documents related to prosecution or issuance of Intellectual Property Rights arising from Jointly Owned Developed Technology for which the party share Joint Costs, which submissions shall be subject to the provisions of
Section 8 (Confidential Information) of this Agreement. 
 7. LICENSES 
 7.1 By Alien. Alien hereby grants to Tower a worldwide, non-exclusive, nontransferable (except pursuant to Section 12.1
below), royalty-free (except as otherwise provided in an applicable SOW), with no right to sublicense (expect as expressly permitted in this Section 7.1) licenses to use any: 
 (a) Existing Technology and other Technology Developed solely by Alien that are owned and licensable by Alien (and the Intellectual
Property Rights of Alien therein), solely to perform Tower’s obligations under this Agreement and under any applicable SOW; 
 (b) Developed Technology jointly Developed by Alien and Tower, that are owned and licensable by Alien (and the Intellectual Property Rights of Alien therein), solely to perform Tower’s obligations under this Agreement and under any
applicable SOW and to make and have made for Alien, use, have used, lease, offer to sell, sell, export or otherwise transfer any products or related processes based on work and deliverables arising from a SOW (including any derivative of such
Developed Technology as described in this sentence), and to practice and have practiced for Alien any method in support of these rights. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 11 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 7.2 By Tower. Tower hereby grants to Alien a worldwide, non-exclusive,
nontransferable (except pursuant to Section 12.1 below), royalty-free (except as otherwise provided in an applicable SOW), with no right to sublicense (expect as expressly permitted in this Section 7.2) licenses to use any: 
 (a) Existing Technology and other Technology Developed solely by Tower that is owned and licensable by Tower (and the Intellectual
Property Rights of Tower therein), to perform Alien’s obligations under this Agreement and under any applicable SOW. 
 (b) Developed Technology jointly Developed by Tower and Alien to the extent owned and licensable by Tower (and the Intellectual Property Rights therein), to perform Alien’s obligations hereunder and under any applicable SOW, and, and
to make at or have made by Tower, use, have used, lease, offer to sell, sell, export, or otherwise transfer any products or processes based on work or deliverables arising from a SOW (including any derivative of such Developed Technology as
described in this sentence), and to practice and have practiced by Tower any method in support of these rights. 
 7.3
Acknowledgments by the Parties. Tower acknowledges that nothing in this Agreement shall restrict Alien’s existing rights to use the Existing Technology or Developed Technology owned by Alien. Except as otherwise provided in
Section 3.3(b), Alien acknowledges that nothing in this Agreement shall restrict Tower’s existing rights to use Existing Technology or Developed Technology owned by Tower. 
 7.4 Rights not Granted. This Agreement grants no license to Tower or to Alien under any other Technology or Intellectual Property
Rights, including all trademarks, not explicitly identified and licensed in this Agreement. 
 8. CONFIDENTIAL INFORMATION 

8.1 Duty to Maintain Confidentiality. Each party agrees to accept Confidential Information from the other party solely for use
in connection with performance of its obligations and exercise of its express rights granted under this Agreement and the executed SOWS and that for a period of five (5) years from the date of disclosure it will hold in strict confidence and not
disclose, publish, or disseminate such Confidential Information, to anyone other than those of its employees and subcontractors with a need to know and have executed appropriate confidentiality agreements, nor use Confidential Information for its
own or any other Party’s benefit, without the prior written approval of an authorized representative of originating Party. The receiving party will protect Confidential Information of the disclosing party from disclosure, publication,
dissemination and unauthorized use with the same degree of care the receiving party uses to protect its own confidential and proprietary information of similar nature, but in no event less than a reasonable degree of care. 
 8.2 Exceptions. The receiving party may disclose Confidential Information if required by operation of law or any tribunal of
competent jurisdiction, provided that it will take reasonable steps to first give the originating party sufficient prior notice to contest the order to disclose, and must cooperate with the originating party in any efforts by the originating party
to obtain a protective order or other confidential treatment. The parties shall have the right to disclose the terms of this Agreement to attorneys, government agencies, financial advisors and potential investors and acquirers (of the party or the
party’s relevant foundry, division, or product line), subject to reasonable confidentiality provisions. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 12 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 8.3 Residuals; No Licenses. The parties acknowledge that exposure to
Confidential Information necessarily will mean that personnel of a receiving party will learn and may retain Residual Information. This Agreement shall not restrict good faith use of Residual Information by personnel of a receiving party as part of
the individual’s generally acquired experience; provided, however, that nothing in this Section 8 shall be deemed to grant any rights under disclosing party Intellectual Property Rights to the receiving party or their personnel in excess
of those license rights expressly granted under Section 7 above. All Confidential Information remains the property of the disclosing party, unless otherwise conveyed under the terms of the Agreement and any license under Intellectual Property
Rights must be express and in writing signed by both parties. 
 8.4 Injunctive Relief. The parties acknowledge that
any breach or threatened breach of the obligations of confidentiality contained in this Section 8 may cause substantial harm to the non-breaching party that may not be reasonably or adequately compensated with monetary damages. Accordingly, in
addition to any other available remedies, the parties recognize each party’s right to seek injunctive relief in connection with such breach or threatened breach. 
 9. TERM; TERMINATION 
 9.1 Term. The term of this Agreement shall begin as of
the Effective Date and continue until December 31, 2006, unless earlier terminated as set forth in this Section 9. The term of this Agreement may be extended by a writing signed by both parties. 
 9.2 Termination of Agreement or Statement of Work for Default. If a party is in Default (as defined below) the other party may, on
written notice terminate either this Agreement or any particular Statement of Work hereunder, with respect to which the other party is in default, subject to the limitations of Section 9.2. “Default” occurs if: 
 (a) a party is in material breach of its obligations under this Agreement or a Statement of Work and such party does not cure such breach
within thirty (30) days after receipt of written notice thereof; 
 (b) a party infringes or threatens to infringe the
Intellectual Property Rights of the other party, breaches or threatens to breach its obligations in respect to the Confidential Information of the other party or is otherwise in breach of its obligations under Sections 7 or 8 of this Agreement; or

 (c) a party makes an assignment for the benefit of its creditors, files a voluntary petition in bankruptcy, is the subject
of an involuntary petition in bankruptcy which is not discharged within sixty (60) days, or applies for or permits the appointment of a receiver or trustee for its assets. The parties’ rights under this Section 9.2 are not exclusive,
but shall be in addition to any rights or remedies provided by law. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 13 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 9.3 Effect of Termination. Termination or expiration of this Agreement shall
terminate all Statements of Work then in effect (but not any payment obligations accrued prior to termination), but the termination of a Statement of Work shall not affect this Agreement or other Statements of Work then in effect. Upon termination
or expiration of this Agreement or any specific Statement of Work: 
 (a) Upon request by the other party, each party shall
return or destroy within 30 days, at the other party’s option, all Confidential Information it received from the other party relating to the terminated Statement of Work, and in the case of termination of the Agreement, all Confidential
Information of the other party; provided however that in either case, each party shall be entitled to retain sufficient copies of those elements of the other party’s Confidential Information as are reasonably necessary to exercise those of its
rights which may survive under subsection (b) immediately below. 
 (b) All definitions contained in this Agreement,
wherever stated, shall survive any termination of this Agreement or any Statement of Work. Further, the following provisions of this Agreement shall survive termination or expiration of the Agreement, and with respect to termination of a Statement
of Work shall survive as to such Statement of Work: Section 1 (Definitions), Section 3.3 (Other Customers), Section 5 (Billing and Payment), Section 6 (Intellectual Property), Section 7.1 (unless the Agreement is terminated
by Alien under Section 9.2), Section 7.2 (unless the Agreement is terminated by Tower under Section 9.2(a) or (b)), Sections 7.3 and 7.4, Section 8 (Confidential Information), this Section 9.3, Section 10 (Disclaimer of
Warranties), Section 11 (Limitation of Liability), and Section 12 (General). 
 (c) If this Agreement or any SOW is
terminated prior to completion of the Services specified in any terminated SOW, then, within thirty (30) days after termination, Tower shall submit invoices for all Services satisfactorily performed and out-of-pocket expenses reasonably
incurred under executed SOWS prior to the effective date of such termination and, only if the Agreement (or the relevant SOW) is terminated by Tower under Section 9.2, an itemized listing of its reasonable expenses resulting from Tower’s
early termination of the Services. Within thirty (30) days after receipt of such statement from Tower, Alien shall remit to Tower payment for any cumulative balance of outstanding invoices. If a SOW provides for Interim Payments or Milestone
Payments, the amount due to Tower for Services performed prior to termination shall be determined as follows: (i) in the case of Interim Payments, (A) all Interim Payments for which the Interim Date has passed but no invoice has been
issued, and (B) the next Interim Payment, multiplied by a fraction, the numerator of which shall be the number of days elapsed from the previous Interim Date until the effective date of termination, and the denominator of which shall be the
total number of days from the previous Interim Date to the next Interim Date; and (ii) in the case of Milestone Payments, (A) all Milestone Payments for which the Milestone has been satisfactorily completed by the Milestone Date but no
invoice has been issued, and (B) the next Milestone Payment, adjusted to reflect the percentage of work toward such Milestone had been completed as of the date of termination, as reasonably determined by the parties. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 14 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 10. DISCLAIMER OF WARRANTIES 
 10.1 No Warranty. ALL INFORMATION, KNOW HOW, TECHNOLOGY AND CONFIDENTIAL INFORMATION SUPPLIED HEREUNDER BY ONE PARTY TO THE OTHER
ARE PROVIDED “AS IS” AND EACH PARTY EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF TITLE, NONINFRINGEMENT, MERCHANTABILITY AND FITNESS
FOR A PARTICULAR PURPOSE. NEITHER PARTY SHALL BE LIABLE TO THE OTHER IF ANY INFORMATION, KNOW-HOW, OR TECHNOLOGY PROVIDED TO THE OTHER PARTY HEREUNDER IS FOUND TO BE INACCURATE, DEFECTIVE, OR INFRINGES THE INTELLECTUAL PROPERTY RIGHTS OF A THIRD
PARTY. 
 11. LIMITATION OF LIABILITY 
 11.1 No Consequential Damages. EXCEPT FOR BREACHES OF DUTY OF CONFIDENTIALITY UNDER SECTION 8, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL,
INCIDENTAL OR PUNITIVE DAMAGES OF ANY TYPE WHATSOEVER, INCLUDING, WITHOUT LIMITATION, LOST GOODWILL, LOST PROFITS, LOSS OF DATA OR SOFTWARE, SERVICES STOPPAGE OR IMPAIRMENT OF OTHER GOODS, AND WHETHER ARISING OUT OF BREACH OF WARRANTY, BEACH OF
CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE OR IF SUCH DAMAGE COULD HAVE BEEN REASONABLY FORESEEN AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY EXCLUSIVE
REMEDY PROVIDED HEREIN. 
 11.2 Limitation of Liability. EXCLUDING ALIEN’S PAYMENT OBLIGATIONS HEREUNDER, A
PARTY’S TOTAL LIABILITY TO THE OTHER PARTY SHALL NOT EXCEED THE TOTAL AMOUNT ACTUALLY PAID BY ALIEN ASSOCIATED WITH THE STATEMENT OF WORK FROM WHICH SUCH LIABILITY AROSE (“LIABILITY CAP”), EXCEPT IN CASES OF BREACHES OF SECTIONS 6, 7
OR 8 WHERE EACH PARTY’S TOTAL LIABILITY SHALL BE LIMITED TO TWICE THE LIABILITY CAP. THE PARTIES AGREE THAT THE FOREGOING REPRESENTS A REASONABLE ALLOCATION OF THE RISK ASSOCIATED WITH THIS AGREEMENT IN LIGHT OF THE FEES TO BE SPECIFIED IN THE
STATEMENT OF WORK. 
 12. GENERAL PROVISIONS 
 12.1 No Assignment. Neither party may assign its rights or obligations under this Agreement or any SOW, in whole or in part, to a
third party without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed. Notwithstanding the foregoing, Tower may assign this Agreement to Tower USA. Further, Tower may make the benefits hereof
available to any entity that succeeds to the business of a particular Tower foundry to the extent such benefit is only associated with the operations of such foundry, subject to the approval of Alien, not to be unreasonably withheld. Any assignment
or attempted assignment in violation of this Section 12.1 shall be null and void. 
 12.2 Entire Agreement;
Amendment. This Agreement, together with its Exhibits, any Statements of Work and Change Orders, constitutes the entire agreement between the parties relating to the subject matter hereof and supersedes all prior agreements, communications, and
statements, whether written or oral, between the parties pertaining to such subject matter. Neither 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 15 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
this Agreement nor any Statement of Work may be modified, changed or amended except by a writing executed by both parties. 
 12.3 Remedies; Waiver. The remedies provided herein are not exclusive, and the party suffering from a breach or default of this
Agreement may pursue all other remedies, both legal and equitable, alternatively or cumulatively. The failure or delay of either party in enforcing any of its rights or remedies under this Agreement shall not be construed to be a waiver of such
right or remedy with respect to any other breach or failure by the other party. 
 12.4 Force Majeure. Neither party
shall be liable for any delay or failure to perform its obligations hereunder resulting from any cause beyond such party’s reasonable control, including but not limited to acts of God, weather, fire, explosions, floods, strikes, accidents,
wars, terrorist attacks or threats thereof, riots or civil disturbances, acts of government, delays by suppliers or material shortages, power outages, or dangerous conditions that pose a threat to either party’s personnel (each, a “Force
Majeure Event”), but only to the extent such Force Majeure Event is beyond such party’s reasonable control. Scheduled performance dates set forth in a Statement of Work shall be reasonably extended by any such cause. 
 12.5 Choice of Law. This Agreement shall be governed and construed in accordance with the laws of the State of California, USA,
excluding its conflicts of law provisions. The parties agree that the United Nations Convention 012 Contracts for the International Sale of Goods shall not apply. 
 12.6 Dispute Resolution. Except as set forth below, the parties will attempt to settle ally claim or controversy arising out of or
relating to this Agreement through consultation and negotiation in good faith and a spirit of mutual cooperation, If those attempts fail, the dispute will be mediated by a mutually acceptable mediator to be chosen by the parties within 45 days after
written notice by one of the parties demanding mediation. Neither party may unreasonably withhold its consent to the selection of a mediator, and the parties will share the cost of the mediation equally. Any dispute that has not been resolved
through negotiation or mediation within six (6) months of the date of the initial demand by either party may then be the subject of judicial proceedings in the appropriate state or federal court in Santa Clara County, California. In the event
of such judicial proceedings or other adversary proceeding, the parties submit to the exclusive personal jurisdiction of, and venue in, the federal and state courts in the State of California and expressly waive any objection thereto.
Notwithstanding anything to the contrary in this Section 12.6, either party may at any time seek judicial relief in any court of competent jurisdiction to enforce its rights with respect to the protection of such party’s Confidential
Information or Intellectual Property Rights hereunder. In any judicial proceeding relating to this Agreement, each party hereby waives its right to a jury trial and agrees that such proceeding shall be tried by a judge without a jury. The use of
alternative dispute resolution will not be construed under the doctrine of laches, waiver or estoppel to affect adversely the rights of either party, and defenses based on the statute of limitations shall be tolled during the alternative dispute
resolution process unless prohibited by applicable law. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 16 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 12.7 Compliance with Laws. Each party will comply with all applicable laws and
regulations governing its activities under this Agreement, including without limitation the export control laws and regulations of the United States with respect to any Confidential Information and/or technical data licensed, delivered, or to which
a party is provided access under this Agreement. The parties agree to cooperate with respect to export compliance, and to execute such export-related documents as the other party may reasonably request. 
 12.8 Interpretation of Agreement. Where this Agreement states that a party “will” or “shall” perform in some
manner or otherwise act or omit to act, it means that the party is legally obligated to do so in accordance with this Agreement. The captions, titles and headings, and table of contents, included in this Agreement are for convenience and reference
only, and do not affect this Agreement’s construction or interpretation. When a reference is made in this Agreement to a Section, Exhibit or a SOW, such reference will be to a Section, Exhibit or a SOW to, this Agreement unless otherwise
indicated. The words “including,” “includes,” or “include” are to be read as listing non-exclusive examples of the matters referred to, whether or not words such as “without limitation” or
“but not limited to” are used in each instance 
 12.9 Notice. All notices required under this
Agreement shall be in writing and addressed to the parties at their respective addresses set forth below. Notices may be delivered personally or sent by telex, courier, facsimile, or registered mail, postage prepaid and shall be effective on the
date of receipt at that address: 
  

			
	 To Tower:
 Tower Semiconductor Ltd.
 Ramat Gavriel Industry Zone
 Migdal Haemek, 23105 Israel
 Attn: Yossi Netzer
 Fax: +972-4-654-7788
	  	 To Alien
 Alien Technology Corporation
 18220 Butterfield Blvd
 Morgan Hill, California 95037, USA
 Attn: Legal Department
 Fax: 408-782-3912

		
	with a copy to:	  	with a copy to:
		
	 Tower Semiconductor USA
 2350 Mission College
Blvd.
 Suite 500
 Santa Clara, CA 95054
 Attn: Ishai Naveh
 Fax: 408-969-9831
	  	 Alien Technology Corporation
 18220 Butterfield
Blvd
 Morgan Hill, California 95037, USA
 Attn: Chief Operating
Officer

 12.10 Severability. If any provision of this Agreement is held by a court or
tribunal of competent jurisdiction to be invalid or unenforceable, such provision shall be enforced to the maximum extent permissible and the remaining portions of this Agreement shall remain in full force and effect. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 17 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 12.11 Counterparts. This Agreement may be executed in one or more
counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 
 12.12 No Obligation for Production Quantities. Neither party is making any commitment or assuming any obligation for production quantities of RFID ICs under this Agreement; any such commitment can only be authorized by the parties in
a separate written supply agreement that is executed by the parties. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 18 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 IN WITNESS WHEREOF, the undersigned have executed this Agreement effective as of the date first set
forth above. 
  

									
	 TOWER SEMICONDUCTOR LTD.
	 		 	 ALIEN TECHNOLOGY CORPORATION

					
	 By: 
	 	 /s/ Doron Simon
	 		 	 By: 
	 	 /s/ John Payne

					
	 Its: 
	 	 VP Mkt.
	 		 	 Its: 
	 	 Chief Operating Officer

	 FAX NUMBER FOR NOTICES: +972-4-654-7788
	 		 	 FAX NUMBER FOR NOTICES: 408-782-3912

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 19 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT A 
 FORM OF STATEMENT OF WORK 
 [***] INTEGRATED CIRCUITS JOINT DEVELOPMENT 
 STATEMENT OF WORK No. 1 
 Tower
Semiconductor Ltd. (“Tower”) agrees to perform the Services described below for Alien Technology Corporation (“Alien”), subject to the terms and conditions set forth in that certain IC Technology Development Agreement by and
between Tower and Alien dated as of 27 May 2005, and as set forth below, and Alien agrees to pay Tower for the Services performed hereunder, as specified below. 
 1. SCOPE OF WORK 
 1.1 All work and services pertain to development of [***] operating
in the [***]. 
 1.2 Product Description: The IC is a low cost passive UHF Radio Frequency Identification tag
(transponder) IC for consumer packaged goods identification and other RFID tagging applications. RF energy transmitted by an RFID reader is received by the tag antenna and coupled to the IC to provide operating power. Upon receipt of valid commands
from the reader, the IC responds by modulating the antenna to reflect incident RF power to the reader. Anti-collision circuitry in the IC enables RFID readers to communicate with all individual tags within a group of tags. Non-volatile memory
enables users to store unique data into tags at the point of application. 
 1.3 General Description of the development
tasks: 
 1.3.1 Process Customization (no charge) - Tower will customize its [***] for the manufacture of UHF RFID
ICs. 
 1.3.2 Device Development (no charge) - Tower will develop [***] for application in UHF RFID ICs. The requisite
process modules will be incorporated into Tower’s [***] and the [***] qualified for production. 
 1.3.3 Digital
Backend Design - Tower will conduct silicon implementation of digital circuitry. Task includes synthesis, place and route, physical verification and back annotation of the layout parasitics for Alien’s [***]. 
 1.3.4 Silicon Fabrication - Tower will provide wafer processing services. Full custom mask sets and shuttle runs are anticipated.

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 1.3.5 Third Party Assistance (no charge) - Tower will support [***] in
development of [***] for use in RFID ICs. Expected support is in the following areas: 
  

	 	•	 	Consultation regarding Tower’s [***] process. 

  

	 	•	 	Design reviews. 

  

	 	•	 	Silicon fabrication utilizing Tower’s shuttle service. 

 2. PROJECT MILESTONES & COMPLETION DATES 
  

					
	 ID
	  	 Milestone Description
	  	Due Date
	 1
	  	[***]	  	[***]
	 2
	  	[***]	  	[***]
	 3
	  	[***]	  	[***]
	 5
	  	[***]	  	[***]
	 6
	  	[***]	  	[***]
	 7
	  	[***]	  	[***]
	 8
	  	[***]	  	[***]
	 9
	  	[***]	  	[***]
	 10
	  	[***]	  	[***]
	 11
	  	[***]	  	[***]
	 12
	  	[***]	  	[***]
	 13
	  	[***]	  	[***]
	 14
	  	[***]	  	[***]
	 15
	  	[***]	  	[***]
	 16
	  	[***]	  	[***]
	 17
	  	[***]	  	[***]
	 18
	  	[***]	  	[***]
	 19
	  	[***]	  	[***]
	 20
	  	[***]	  	[***]
	 21
	  	[***]	  	[***]
	 22
	  	[***]	  	[***]
	 23
	  	[***]	  	[***]
	 24
	  	[***]	  	[***]
	 25
	  	[***]	  	[***]
	 26
	  	[***]	  	[***]
	 27
	  	[***]	  	[***]
	 28
	  	[***]	  	[***]
	 29
	  	[***]	  	[***]
	 30
	  	[***]	  	[***]

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -2- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 3. PARTY RESPONSIBILITIES 
 3.1 Tower will be primarily responsible for: 
 3.1.1 [***] development 
 3.1.2 Basic device test structures and test structure
characterization 
 3.1.3 Design support, including physical and electrical design rules, DRC/LVS runsets, SPICE models,
design kits, and RCE extraction runsets; 
 3.1.4 [***] protection consulting 
 3.1.5 Digital back-end design (pending [***] characterization of standard cells library by Alien) 
 3.1.6 Wafer fabrication 
 3.1.7 Process-control monitor (PCM) scribe-line test chip design and characterization, and electrical test for [***] of finished wafers 
 3.1.8 Process quality and reliability testing and assurance 
 3.1.9 Sort results, Product wafer probe, upon agreement with Alien. 
 3.1.10 Yield improvement activity after product ramp 
 3.2 Alien will be primarily responsible for: 
 3.2.1 RF/analog design & layout (per product definition) 
 3.2.2 [***] protection
development 
 3.2.3 Digital front-end design 
 3.2.4 Library timing characterization for [***] operation 
 3.2.5 [***] from [***] ([***]) 
 3.2.6 Chip elements integration, merge, closure and sign-off 
 3.2.7 Chip assembly &
verification 
 3.2.8 Process compatibility of NanoBlock ICs to Tower’s process 
 3.2.9 Alien-specific test vehicle design (SLE) 
 3.2.10 Test vehicle testing and characterization 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -3- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 3.2.11 Wafer sort program: Product test program specification, development/debug,
release to production, and production test hardware per agreement. 
 3.2.12 Product verification and testing 
 3.2.13 Product quality and reliability testing and assurance 
 3.2.14 Product qualification, including any necessary hardware/software and analysis services 
 3.2.15 Package-level and device characterization 
 3.2.16 Reports: yield results, FT data, product qualification data 
 4. DELIVERABLES 
 4.1
Tower deliverables : 
 4.1.1 [***] from each shuttle run 
 4.1.2 SLE wafers run for Alien mfg process development 
  

	 	•	 	NanoBlock wafer map 

  

	 	•	 	Create specific process to comply with Alien special street configuration 

  

	 	•	 	Define additional required masks to comply with Alien special street 

  

	 	•	 	Define specific rules to comply with RFID edge protection during NanoBlock fabrication 

 4.1.3 EEPROM test chips from shuttle run (depends on [***] permission) 
 4.1.4 Final [***] design kit (see exhibit A-1) 
  

	 	•	 	[***] design rules 

  

	 	•	 	[***] technology files for Calibre and X-Calibre 

  

	 	•	 	[***] SPICE models 

  

	 	•	 	[***] specifications, GDSII and SPICE models 

  

	 	•	 	[***] characterization report 

 4.1.5 [***]
design - consult with possible [***] structures and reference designs that comply with RFID constrains 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -4- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 4.1.6 Specific technology for Higgs project (see exhibit A-1) 
  

	 	•	 	Design under pad 

  

	 	•	 	Thin top metal 

  

	 	•	 	[***] 

  

	 	•	 	Streets protection 

  

	 	•	 	MIM for Thin top metal configuration 

 4.1.7 RFID chip silicon wafers 
 4.1.8 Design review attendance 
  

	 	•	 	EEPROM 

  

	 	•	 	RFID IC 

 4.1.9 [***] design 
  

	 	•	 	Synthesized gate netlist of digital block 

  

	 	•	 	GDS I1 database of digital block 

  

	 	•	 	Back annotated Gate-Level netlist (.v) and SDF 

  

	 	•	 	Extraction Data for PrimeTime (DSPF or SPEF) 

  

	 	•	 	CDL netlist of digital block 

  

	 	•	 	Verification report for digital block 

 4.2
Alien deliverables 
 4.2.1 [***] measurement 
 4.2.2 Analog/RF Test chip GDSII 
 4.2.3 ESD Test chip GDSII 
 4.2.4 Short loop Experiment (SLE) GDSII for mfg process
development 
 4.2.5 RFID chip GDS I1 database (DRC clean) 
  

	 	•	 	1 tape-out: 

  

	 	•	 	2nd tape-out: B/E masks only 

  

	 	•	 	3rd tape-out: 

 Alien will provide [***] at least one week
before tapeout to Tower, to allow sufficient time for an interactive work on the reticle and wafer map optimization. 
 4.2.6
[***] design 
  

	 	•	 	Cell characterization for [***] 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -5- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	•	 	Verilog code 

  

	 	•	 	Synthesis constraints 

  

	 	•	 	Place and route constraints 

  

	 	•	 	Verification review 

  

	 	•	 	Guidelines for spare gate insertion 

 5.
QUALIFICATION & PRODUCTION READINESS 
 5.1 Qualification 
 5.1.1 Technology qualification is based on [***]. 
 5.1.2 The RFID Product qualification will be conducted by Alien. The qualification report will be provided to Tower. 
 5.1.3 [***] module qualification is under Alien responsibility. 
 5.1.4 Assembly process (NanoBlock) qualification is under Alien responsibility. Tower will provide the required support to qualify product
assembly 
 5.2 Test 
 5.2.1 Sample sort methodology at EOL will be considered for process control at Tower 
 5.2.2
General guidelines 
  

	 	•	 	Test platform - Two options can be considered: Nextest Maverick, or an existing digital sort platform at Tower. 

  

	 	•	 	Sort wafer map to be determined according to prober limitations. 

  

	 	•	 	Sort program transfer and correlation exercise are still to be defined. 

  

	 	•	 	Final details are still to be defined and agreed. 

 6.
SPECIFICATIONS 
 6.1 RFID IC: 
  

					
	6.1.1	  	Chip size:	  	[***]
			
	 6.1.2
	  	RF operating frequency:	  	[***]
			
	 6.1.3
	  	Min. operating Vdd:	  	[***]
			
	 6.1.4
	  	Max. Operating Vdd:	  	[***]

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -6- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 6.1.5 Idd at min. operating Vdd: [***] 
 6.1.6 Operating temperature: [***] 
 6.2 Memory: 
 6.2.1 RFID [***] Specification No. [***] 
 6.2.2 Alien-[***] SOW: [***] 
 6.2.3 [***] Qualification Plan as referenced in [***] 
 6.3 [***] 
 6.3.1 [***] specifications @ Room Temperature: [***] 
 6.3.2 [***] specifications @ Room Temperature: [***] 
 Notes: 
  

	 	•	 	For each [***], the monitor is the calculated value from measurements taken on a [***] array 

  

	 	•	 	[***] specifications will be finalized after sufficient PCM data collection 

  

	 	•	 	Tower [***] SPICE models adequately capture total anticipated device variation with process and temperature for the above parameters 

 6.4 [***] and Latch up goals for design (Alien’s responsibility) 
 6.4.1 [***] 
 6.4.2 [***] 
 6.4.3 [***] (relevant in Alien RFID strap package) 
 6.4.4 [***] 
 7. PROJECT
MANAGEMENT 
 7.1 Project management group consists of Tower’s Program Manager, Alien’s Program Manager, and
individuals, Focal Points, responsible for major tasks of the project. In support of successful task completion, this group is responsible for: 
  

	 	•	 	Coordinating the effort of the respective team members per project requirements. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -7- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	•	 	Making the required information, code, data and knowledge available to the respective parties per the project requirements. 

  

	 	•	 	Monitoring project progress and impact of any issues that may arise during the project execution 

  

	 	•	 	Coordinating events during the change resolution process. 

  

	 	•	 	Arranging periodic status meetings and project reviews at the completion of each major milestone / deliverable or in case an escalation is required 

 7.2 Project Contacts 
  

					
	 Project Contact Position
	  	 Name
	  	 Company

	Project Manager	  	 Yosi Netzer
 yosin@towersemi.com
 972-4-6506486
	  	Tower (Israel)
			
	Logistics & Program Management	  	 Eyal Bendory
 eyalbe@towersemi.com
 972-4-6506649
	  	Tower (Israel)
			
	Technology Line manager	  	 Isahi Naveh
 ishai@towersemi.com
 (408) 330-6898
	  	Tower (USA)
			
	Sales	  	 Waqas Khan
 Waqas@nxs.com
 (510) 364-2183
	  	Tower (USA)
			
	Project Sponsor	  	 Iszhak Edrei
 iszhake@towersemi.com
 972-4-6506577
	  	Tower (Israel)
			
	Project Manager	  	 John Rolin
 jrolin@alientechnology.com
 (408) 782-3934
	  	Alien
			
	Manufacturing Process Lead	  	 Eric Snyder
 esnyder@alientechnology.com
 (408) 782-3993
	  	Alien
			
	Business Interface	  	 John Payne
 jpayne@alientechnology.com
 (408) 782-3921
	  	Alien
			
	Project Sponsor	  	 Jim Atherton
 jatherton@alientechnology.com

(408) 782-3924
	  	Alien

 7.3 Focal persons will be assigned in both parties for the following areas:

 7.3.1 DesignICAD and TI0 procedure 
 7.3.2 [***] concepts, simulations and design 
 7.3.3 Characterization (CZ) of product & [***] test-chips 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -8- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 7.3.4 Process engineering (around the NanoBlock module and its implications)

 7.3.5 Product testing 
 7.4 Escalation 
 7.4.1 The Program Managers of each party will act as the overall
point-of-contact in resolving any consulting execution or delivery issues between the parties. 
 7.4.2 When the specific
project manager is not able to provide and/or achieve resolution, the matter will be escalated to the project sponsors, in order to decide on further resolution steps. 
 7.4.3 In a case of a persistent unresolved matters problem or a crash, a special meeting will be held with the relevant engineering and
managerial resources from both parties at a time and place mutually greed upon. 
 8. FEES AND EXPENSES 
 8.1 NanoBlock SLE 
  

	 	•	 	N/A 

 8.2 Multi-project shuttle 

 

	 	•	 	[***] 

  

	 	•	 	[***] 

 8.3 [***] design 
  

	 	•	 	[***] 

 8.4 Full custom fabrication run

  

	 	•	 	[***] 

  

	 	•	 	[***] 

 9. REFERENCE DOCUMENTS 
  

	 	•	 	JDA - IC Technology Development Agreement 

  

	 	•	 	Exhibits - B, C, D 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -9- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 10. ADDITIONAL TERMS: 
 10.1 [***] - as per the JDA 
 11. APPROVAL 
 This Statement of Work has been entered into this 27th day of May, 2005. 
 Each party hereby acknowledge that they have read and understand this Statement of Work 
  

									
	TOWER SEMICONDUCTOR LTD.	 		 	ALIEN TECHNOLOGY CORPORATION:
					
	By:	 	/s/ Doron Simon	 		 	By:	 	/s/ John Payne
		 	Doron Simon	 		 		 	John Payne
					
	Its:	 	VP Mkt.	 		 	Its:	 	Chief Operating Officer

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -10- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT B 
 APPENDIX TO STATEMENT OF WORK 
 TOWER PROCESS & TECHNOLOGY IMPLEMENTATION CHECKLIST

 [***] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT C 
 APPENDIX TO STATEMENT OF WORK 
 FORM OF CHANGE ORDER 
 Tower Semiconductor Ltd. (“Tower”) and Alien Technology Corporation (“Alien”), subject to the terms and conditions set forth in that
certain IC Technology Development Agreement by and between Tower and Alien dated as of 27 May 2005, hereby agree to modify Statement of Work No. 1 entered into there under and dated as of 27 May, 2005 (the “Statement of
Work”) as follows: 
 (attach other sheets if necessary) 
 Other than as modified herein, or as modified by other Change Orders with respect to the Statement of Work that have been or may be entered into between Alien and Tower, the Statement of Work remains in full force and
effect. 
 The parties have entered into this Change Order as of _______________, 200___. 
  

									
	 TOWER SEMICONDUCTOR LTD.
	 		 	 ALIEN TECHNOLOGY CORPORATION:

		 		 	  
					
	 By:
	 	  	 		 	 By:
	 	  
		 	 [name]
	 		 		 	 [Insert name]

					
	 Its:
	 	  	 		 	 Its:
	 	  

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 -2- 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT D 
 APPENDIX TO STATEMENT OF WORK 
 LIST OF INTELLECTUAL PROPERTY RIGHTS AND LICENSES 

 

	1.	Tower 

  

	 	1.1	[***] 

  

	 	1.2	[***] 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 [***] STATEMENT OF WORK 
 WHEREAS, Alien and Tower have entered into that certain IC Technology Development Agreement, dated the 27th of May 2005 (“Agreement”), and the parties desire to enter into this [***] Statement of Work as a statement of work to that Agreement (as amended
hereby) for Alien’s [***] product; and 
 WHEREAS, in consideration of Tower performing the development activities under this Statement of Work intended
for use as part of Alien’s [***] product, and subject to Alien and Tower agreeing upon [***] for Tower to supply wafers that include Alien’s [***] product, Alien has (a) committed to [***] (“Tower Outsourced Products”) at
Tower, [***], and (b) granted to Tower [***] with respect to the Alien’s manufacturing needs of [***] of the Tower Outsourced Products (i.e., [***]) such right to be exercised as set forth in Exhibit C hereto. The parties will make
commercially reasonable diligent efforts in good faith to negotiate and conclude a foundry agreement for the supply of IC products to Alien by Tower by [***]. 
 Project Name: [***] 
 STATEMENT OF WORK No. 2 
 Tower Semiconductor Ltd. (“Tower”) agrees to perform the Services described below for Alien Technology Corporation (“Alien”), subject to the terms and
conditions set forth in the Agreement, and as set forth below, and Alien agrees to pay Tower for the Services performed hereunder, as specified below. 
 SCOPE OF WORK 
  

	1	Product Description: 

 Based on Tower’s proprietary
patented [***], Tower will design a [***] module in accordance with the Specifications attached to this SOW (the “Module”), and make commercial reasonable best efforts to meet the requirements of such specifications with the purpose of
integrating such Module into a product of Alien (the “Product”). The main features of the Module are: [***]; very low power consumption, very small area, and robustness [***] defined in the Specifications. 
  

	 	1.1	General Description of the development tasks required for the Module: 

  

	 	1.1.1	 Process – The Module will be based on the same Tower [***] process flow that is used for the current Alien products under development, as specified in reference 1.
[***] 

  

	 	1.1.2	 Device Development 

 The [***] cell in the
Module is based on Tower’s [***]. The cell, [***], will be designed to meet the Specification. Supporting devices may be developed, as needed. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	1.1.3	 Design. 

 Tower will design: 
  

	 	1.1.3.1	A test chip for the [***], which will serve as a development platform for cell design changes and investigating the optimal work conditions for the [***] cells.

  

	 	1.1.3.2	The Module, including [***]. Tower will deliver to Alien the EDA views specified in Section 4.1.1 necessary to enable smooth integration of the Module into Alien’s RFID
product. 

  

	 	1.1.3.3	A test chip for the Module ([***] – module level test chip) to be tested, verified and qualified by Tower to prove the Module functionality and reliability.

  

	 	1.1.4 	Silicon Fabrication and Testing 

 Tower will
fabricate on its manufacturing process (placing the test chips on a “shuttle” reticle) and test both the [***] and the [***]. 
  

	2	PROJECT MILESTONES & ESTIMATED COMPLETION DATES 

  

							
	ID	  	 Milestone
	  	Estimated Due Date
(Relative)	 	Estimated Due
Date
				
	1	  	 [***]
	  	[***]	 	[***]
				
	2	  	 [***]
	  	[***]	 	[***]
				
	3	  	 [***]
	  	[***]	 	[***]
				
	4	  	 [***]
	  	[***]	 	[***]
				
	5	  	 [***]
	  	[***]	 	[***]
				
	6	  	 [***]
	  	[***]	 	[***]
				
	7	  	 [***]
	  	[***]	 	[***]
				
	8	  	 [***]
	  	[***]	 	[***]
				
	9	  	 [***]
	  	[***]	 	[***]
				
	10	  	 [***]
	  	[***]	 	[***]
				
	11	  	 [***]
	  	[***]	 	[***]
				
	12	  	 [***]
	  	[***]	 	[***]

 Comment: The list above contains the major milestones, detailed project planning will be established during
project kick-off. For purposes of this SOW, (i) “T0” means the Effective Date of this SOW, and (ii) “W” means calendar week. 
 Without limiting other remedies available, in the event Tower fails to meet any of the “Key Milestones” (as defined below) within [***] days after its Estimated Due Date in the chart listed above without any fault on Alien’s
part, Alien may terminate this SOW by delivery of written notice to Tower, and in such case the provisions of Section 9.3(c) of the Agreement (Effect of Termination Prior to Completion of the Services) shall apply. [***]. In no event of
termination by Alien will Tower be entitled to fees and/or expenses that are in excess of the amount set forth in Section 8 of this SOW. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	3	PARTY RESPONSIBILITIES 

  

	 	3.1	Tower will be primarily responsible for: 

  

	 	3.1.1 	Deliver appropriate device test chips and related electrical test programs for the Module production monitoring 

  

	 	3.1.2 	Designing, testing and characterizing an array level test-chip of [***]. 

  

	 	3.1.3 	Participating in the following inter-company reviews: 

  

	 	(a)	Preliminary and final design reviews, to be held prior to [***]. 

  

	 	(b)	Layout review to ensure compatibility with Product requirements, to be held prior to [***]. 

  

	 	3.1.4 	Designing the Module and a test chip and creating the following [***] views for the Module: data Sheet, behavioral model, integration guidelines, physical abstract (LEF), timing
views, and antenna LEF. 

  

	 	3.1.5 	Testing, characterizing and qualifying the test chip for the Module according to agreed upon characterization and qualification plans 

  

	 	3.2	Alien will be primarily responsible for: 

  

	 	3.2.1 	Defining the Specifications for the Module 

  

	 	3.2.2 	Defining the [***] used in the Alien tool flow 

  

	 	3.2.3 	Integrating the Module in the Product 

  

	 	3.2.4 	Participating in the following inter-company reviews: 

  

	 	(a)	Preliminary and final design reviews, [***]. 

  

	 	(b)	Layout review to ensure compatibility with Product requirements, [***]. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	4	DELIVERABLES 

  

	 	4.1	Tower will provide the following deliverables (“Tower Deliverables”) per the estimated schedule listed in Section 2 of the SOW: 

  

	 	4.1.1	 The following [***] for the Module: 

 Module Data
Sheet 
 Behavioral Model 
 Integration Guidelines 
 GDS abstract View 
 GDS database View 
 Timing View 
 Antenna LEF 
  

	 	4.1.2 	The following characterization and qualification reports: 

  

	 	4.1.2.1	 [***] report 

  

	 	4.1.2.2	 [***] characterization report 

  

	 	4.1.2.3	 Module test chip characterization report 

  

	 	4.1.2.4	 Module Qualification report 

  

	 	4.2	Alien will provide the following deliverables (“Alien Deliverables”): 

  

	 	4.2.1 	Module Specifications 

  

	5	Acceptance  

  

	 	5.1	Characterization 

  

	 	5.1.1 	Module characterization plan is attached as Exhibit D 

  

	 	5.2	Qualification 

  

	 	5.2.1 	Module Qualification plan is attached as Exhibit E 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	6	SPECIFICATION & DATASHEET 

 Module
Specifications 
 [***] 
 Preliminary Module Datasheet 
 [***] 
 The parties agree that Alien may request within 2 weeks of the Effective Date of this SOW to change the Module [***] without incurring material impact on the project schedule and datasheet. As of the Effective Date, Alien hereby requests
that Tower change the Module [***], and Tower acknowledges such request. 
  

	7	PROJECT MANAGEMENT 

  

	 	7.1	Project management group consists of Tower’s Program Manager, Alien’s Program Manager, and individuals, Focal Points, responsible for major tasks of the project.

 In support of successful task completion, this group is responsible for: 
  

	 	•	 	Coordinating the effort of the respective team members per project requirements. 

  

	 	•	 	Making the required information, code, data and knowledge available to the respective parties per the project requirements. 

  

	 	•	 	Monitoring project progress and impact of any issues that may arise during the project execution 

  

	 	•	 	Coordinating events during the change resolution process. 

  

	 	•	 	Arranging periodic status meetings and project reviews at the completion of each major milestone / deliverable or in case an escalation is required 

  

	 	7.2	Project Contacts 

  

					
	 Project Contact Position
	  	 Name
	  	 Company

	 Project Manager
	  	 Limor Kendler Levy
	  	 Tower

			
	 Sales / Marketing
	  	 Ishai Naveh
	  	 Tower

			
	 Project Sponsor
	  	 Yossi Netzer
	  	 Tower

			
	 Project Manager
	  	 James Atherton
	  	 Alien

			
	 Business Interface
	  	 John Payne
	  	 Alien

			
	 Project Sponsor
	  	Natalino Camilleri	  	Alien

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	7.3	Escalation 

  

	 	7.3.1 	The Program Managers of each party will act as the overall point-of-contact in resolving any consulting execution or delivery issues between the parties. 

 

	 	7.3.2 	When the specific project manager is not able to provide and/or achieve resolution, the matter will be escalated to the project sponsors, in order to decide on further resolution
steps. 

  

	 	7.3.3 	In a case of a persistent unresolved matters problem or a crash, a special meeting will be held with the relevant engineering and managerial resources from both parties at a time
and place mutually agreed upon. 

  

	 	7.4	Inspection 

  

	 	7.4.1 	Upon Alien’s request, Tower shall provide detailed information, reports and materials requested by Alien that describe Tower’s progress towards any Milestone and/or with
respect to any Tower Deliverables. 

  

	 	7.4.2 	Upon Alien’s request, Tower shall provide access to Tower’s facilities and other locations where Tower activities hereunder are being performed for the purpose of
verifying Tower’s progress towards any Milestone or any Tower Deliverable. 

  

	8	FEES AND EXPENSES 

 For the overall
development listed in the SOW, subject to the terms and conditions herein, Alien will pay Tower [***] in accordance with the following payment schedule: 
  

					
	 Milestone
	  	 Percent of Payment
	  	 Comments:

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	
	 [***]
	  	 [***]
	  	
	 [***]
	  	 [***]
	  	

  

	9	REFERENCE DOCUMENTS 

  

	 	9.1	“Agreement” (as defined in the opening paragraph to this SOW) 

  

	 	9.2	“Previous SOW” 

  

	 	9.3	“Specifications” ([***]) 

  

	 	9.4	Module Characterization plan – Exhibit D 

  

	 	9.5	Module Qualification plan – Exhibit E 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	10	OWNERSHIP, LICENSE & CONFIDENTIALITY 

  

	 	10.1 	Notwithstanding anything in Section 6 of the Agreement, Tower shall solely own the Module including all Tower Deliverables, devices, circuitry and components.

  

	 	10.2 	Subject to the payment of the fees listed in Section 8 of this SOW, Alien is granted the licenses listed in Section 7.2 of the Agreement with respect to the Tower
Deliverables listed in Section 4 of this SOW. Except as expressly set forth in this SOW and in the Agreement, Alien may not disclose, distribute or modify the Module and any of the Tower Deliverables. The manufacture of any integrated circuits
containing either any portion of the Module and any of the Tower Deliverables or any [***] that is derived from the Module, the Tower Deliverables or the datasheet (except to the extent reflecting the Specifications) or other deliverables provided
by Tower under this Agreement, may occur only at Tower’s manufacturing facilities (or as otherwise approved by Tower in writing). In accordance with the pre-existing confidentiality provisions between the parties, the Module and any of the
Tower Deliverables are Confidential Information of Tower and may not be disclosed to any third parties and may be used only as authorized hereunder and only by Alien employees with a need to know in order to design and layout integrated circuits
using the Module and any of the Tower Deliverables solely to be manufactured at Tower’s manufacturing facilities (provided however that Alien’s distribution RFID products, and related marketing and sales activities related thereto, that
include the Module and any of the Tower Deliverables shall not constitute breach of Tower’s Confidential Information). Certain elements of the Module and any of the Tower Deliverables may be provided to Alien in files/data formatted for use
with or by certain third party tools/products. No license to any third party tools/products is granted to Alien by Tower under this Agreement. Alien must ensure that it has the necessary licenses and rights to use the third party tools/products
necessary to utilize the Module and any of the Tower Deliverables. 

  

	 	10.3 	Each of the parties acknowledge that the other has contributed Confidential Information to both the Module Specification and the Module Data Sheet, and hereby agree upon the
following treatment of such Confidential Information: 

  

	 	10.3.1	 Tower agrees that it will not disclose the Alien Confidential Information in the Module Specification to any third party except as expressly permitted by the terms of the
Agreement concerning the treatment of Confidential Information. Tower agrees that Alien may disclose the Tower Confidential Information in the Module Specification to third parties under a nondisclosure agreement at least as protective of
Tower’s interests as the terms of the Agreement concerning the treatment of Confidential Information, and that any terms in the Agreement or this SOW notwithstanding, Alien may retain the Tower Confidential Information in the Module
Specification following the termination of the Agreement or this SOW. 

  

	 	10.3.2	  Alien agrees that it will not disclose the Tower Confidential Information in the Module Data Sheet to any third party except as expressly permitted by the

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	 
terms of the Agreement concerning the treatment of Confidential Information. Alien agrees that Tower may disclose the Alien Confidential Information in the
Module Data Sheet to third parties under a nondisclosure agreement at least as protective of Alien’s interests as the terms of the Agreement concerning the treatment of Confidential Information, and that any terms in the Agreement or this SOW
notwithstanding, Tower may retain the Alien Confidential Information in the Module Data Sheet following the termination of the Agreement or this SOW. 

  

	11	ADDITIONAL TERMS: 

  

	 	11.1	Each party represents that it has the right to enter into this SOW 

  

	 	11.2	Indemnification by Tower. Subject to the terms and conditions of the Agreement and this SOW, including the provisions of Sections 10 and 11 of the Agreement and this
Section 11 of the SOW, Tower shall defend, or at its option, settle any claim, suit or proceeding brought by a third party against Alien or its officers, directors or employees (an “Infringement Proceeding”) to the extent such
Infringement Proceeding is based on any claim that the Tower Deliverables directly infringes or misappropriates any copyright, trade secret or U.S. patent, and shall pay any settlement amounts or damages finally awarded in such Infringement
Proceeding; provided, however, that Alien (i) promptly notifies Tower in writing of such Infringement Proceeding; (ii) gives Tower sole control over the defense and/or settlement of such Infringement Proceeding; (iii) does not make
any admission of liability nor settle or otherwise compromise any such Infringement Proceeding without Tower’s prior written consent; (iv) reasonably cooperates and provides Tower with all available information, assistance, and authority
to defend or settle the Infringement Proceeding. Tower shall not enter into any settlement or consent decree that results in an admission of liability by Alien or the entry of injunctive relief against Alien without Alien’s prior written
consent, which consent shall not be unreasonably withheld or delayed. Tower shall not be liable for any costs, expenses, damages or fees incurred by Alien in defending such action or claim unless authorized in advance in writing by Tower

  

	 	11.3	Mitigation. If the use of any Tower Deliverable is, or in Tower’s opinion is likely to become, enjoined or the subject of an Infringement Proceeding, Tower may, and in
the event the use of any Tower Deliverable is enjoined, Tower shall: (a) obtain, at no cost to Alien, the right to continue the use such Tower Deliverable; or (b) replace or modify such Tower Deliverable, at no cost to Alien, with a
non-infringing Tower Deliverable; provided that if (c) Tower cannot obtain for Alien the right to use such Tower Deliverable on a commercially reasonable basis, and cannot on a commercially reasonable basis replace or modify such Tower
Deliverable to make it non-infringing, Tower may terminate this SOW and refund the fees paid by Alien for the applicable Tower Deliverable(s), at which point Alien shall cease use of the applicable Tower Deliverable. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	11.4	Exclusions. Tower shall not be responsible and have no liability with respect to any Infringement Proceeding, or portion thereof, to the extent it is based on or results
from: (i) any combination, operation or use of any Tower Deliverable with materials, manufacturing or equipment not furnished by Tower; (ii) Tower’s compliance with Alien’s written direction designs, Specifications or
instructions, including authorized use of Alien technical information; (iii) any act, omission, design and/or Specification of Alien, including any modification or unauthorized or unlicensed use of the Tower Deliverables by Alien or its
customers. 

  

	 	11.5	Sole Remedy. TOWER’S OBLIGATIONS AND ALIEN’S RIGHTS UNDER SECTIONS 11.1, 11.2 AND 11.3 ARE TOWER’S SOLE OBLIGATIONS AND ALIEN’S SOLE REMEDIES, ARISING OUT
OF OR RELATED TO INFRINGEMENT OR MISAPPROPRIATION OF INTELLECTUAL PROPERTY RIGHTS. 

  

	 	11.6	Indemnification by Alien. Subject to the terms and conditions of the Agreement and this SOW, including the provisions of Sections 10 and 11 of the Agreement and this Section
11 of the SOW, Alien shall defend, or at its option, settle any claim, suit or proceeding brought by a third party against Tower or its officers, directors or employees (an “Infringement Proceeding”) to the extent such Infringement
Proceeding is based on any claim that either the Alien Deliverables or the Tower Deliverables, as a result of a modification by Alien or combination of the Tower Deliverables with other equipment, technology or software not purchased or licensed
from Tower, directly infringes or misappropriates any copyright, trade secret or U.S. patent, and shall pay any settlement amounts or damages finally awarded in such Infringement Proceeding; provided, however, that Alien (i) promptly notifies Tower
in writing of such Infringement Proceeding; (ii) gives Tower sole control over the defense and/or settlement of such Infringement Proceeding; (iii) does not make any admission of liability nor settle or otherwise compromise any such Infringement
Proceeding without Tower’s prior written consent; (iv) reasonably cooperates and provides Tower with all available information, assistance, and authority to defend or settle the Infringement Proceeding. Tower shall not enter into any settlement
or consent decree that results in an admission of liability by Alien or the entry of injunctive relief against Alien without Alien’s prior written consent, which consent shall not be unreasonably withheld or delayed. Tower shall not be liable
for any costs, expenses, damages or fees incurred by Alien in defending such action or claim unless authorized in advance in writing by Tower. ALIEN’S OBLIGATIONS AND TOWER’S RIGHTS UNDER SECTIONS 11.6 ARE ALIEN’S SOLE OBLIGATIONS AND
TOWER’S SOLE REMEDIES, ARISING OUT OF OR RELATED TO INFRINGEMENT OR MISAPPROPRIATION OF INTELLECTUAL PROPERTY RIGHTS. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	11.7	Except for Alien’s benefit as specified in the Agreement and any SOW related thereto, [***]. The limitation set forth in the preceding sentence shall survive expiration of the
Agreement and / or this SOW, but shall not survive in the event the Agreement or this SOW is terminated by either party. 

  

	 	11.8	The Term of the Agreement is extended until December 31, 2007; provided, however, that those elements of this SOW (including Exhibit C hereto) concerning the parties’ rights
and obligations with respect to the purchase and sale of Tower Outsourced Products shall extend until December 31, 2009, as shall any terms which are required to survive the expiration of the Term in order for the parties to exercise such rights and
fulfill such obligations. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 APPROVAL 
 This Statement of Work has been entered into this 1st day of March, 2006 (the “Effective Date”). 
 Each party hereby acknowledge that
they have read and understand this Statement of Work 
  

									
	 TOWER SEMICONDUCTOR LTD.
	 		 	ALIEN TECHNOLOGY CORPORATION:
					
	BY:	 	 /s/ FRA DRUMM
	 		 	 BY:
	 	/s/ JOHN PAYNE
		 	Fra Drumm	 		 		 	John Payne
					
	ITS:	 	VP & GM TOWER USA	 		 	 ITS:
	 	CHIEF OPERATING OFFICER

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT A 
 APPENDIX TO STATEMENT OF WORK 
 TOWER PROCESS & TECHNOLOGY IMPLEMENTATION CHECKLIST

  

	1.	Technology Implementation Checklist: 

  

	 	1.1	Design Rules Spice models and [***] 

  

	 	1.2	Module specific Design Rules and [***] will be defined at a later stage if required 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT B 
 APPENDIX TO STATEMENT OF WORK 
 FORM OF CHANGE ORDER 
 Tower Semiconductor Ltd. (“Tower”) and Alien (“Alien”), subject to the terms and conditions set forth in that certain IC Technology
Development Agreement by and between Tower and Alien dated as of XXXX, hereby agree to modify Statement of Work No. ___ entered into there under and dated as of __________ ___, 200___ (the “Statement of Work”) as follows: 
 (attach other sheets if necessary) 
 Other than as modified
herein, or as modified by other Change Orders with respect to the Statement of Work that have been or may be entered into between Alien and Tower, the Statement of Work remains in full force and effect. 
 The parties have entered into this Change Order as of ________________, 200__. 
  

									
	 TOWER SEMICONDUCTOR LTD.
	 		 	 ALIEN TECHNOLOGY CORPORATION:

					
	BY:	 	  	 		 	 BY:
	 	  
		 	 [name]
	 		 		 	 [Insert name]

					
	 ITS:
	 	  	 		 	 ITS:
	 	  

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT C 
 APPENDIX TO STATEMENT OF WORK 
 [***] 
  

	(1)	[***] 

  

	(2)	[***] 

  

	(3)	[***] 

 [***] Tower agrees that it will supply the agreed wafer
requirements to Alien provided that Alien meets the forecast, lead time, and other commercial requirements in the Foundry Agreement between Alien and Tower, or if no such Foundry Agreement is in place, Tower’s standard forecast, lead-time and
other commercial requirements for products in the class of the Tower Outsourced Products. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT D 
 APPENDIX TO STATEMENT OF WORK 
 MODULE CHARACTERIZATION PLAN 
  

							
	Title: Module characterization plan
	
	REVISION HISTORY
				
	 Rev
	  	 Originator
	  	 Date
	  	 Page/Paragraph - Changed Deleted

	 1.0
	  	Tóth Tamás	  	Nov. 15 2005	  	Initial Criteria
	 2.0
	  	Limor Levy-Kendler	  	Dec 21, 2005	  	Adjust per biz/customer requirements
	 3.0
	  	Ohad Kritz	  	March 2, 2006	  	Terminology Alignment with the SOW

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	1.	General 

 This document describes the characterization plan for the Tower
Module, [***]. The following sections detail the electrical tests required to determine the functionality and manufacturability of the Tower Module. 
 Description of the Test Conditions: 
 Quantity – [***] 
 Tested Parameters – [***] 
 Operating Temperature: [***] 
 Operating Voltage: [***] 
                                 [***] 
 Output – [***] 
  

	2.	Module Diagram 

 [***] 
 Figure 1. MTEG Architecture 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 2.1 AC Characteristics – Read 
 [***] 
 2.2 AC Characteristics – Write 
 [***] 
 2.3 AC Characteristics – Erase 
 [***] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 EXHIBIT E 
 APPENDIX TO STATEMENT OF WORK 
 MODULE QUALIFICATION PLAN 
  

											
	Title: TS18 TNV 1K Cycles Technology Qualification Plan
		
	Number: RAI2 070	  	1.0
	
	REVISION HISTORY
					
	 Rev
	  	 Originator
	  	 Date
	  	By	  	 Page/Paragraph - Changed Deleted

	 1.1
	  	Efraim Aloni	  	13/11/2005	  	TE	  	
	 1.2
	  	Ohad Kritz	  	02/03/2006	  		  	Terminology alignment with the SOW
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 QUALIFICATION PLAN 
 TS18 TNV 1K CYCLES TECHNOLOGY 
  

					
	 Responsible Engineer:
	  	Amos Fenigstein	 	(Tel: 6080)
			
	 Originator:
	  	Efraim Aloni	 	(Tel: 6673)
			
	 Fab:
	  	2	 	
			
	 Area:
	  	New Technology	 	

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	1.	PURPOSE AND SCOPE 

 The purpose of this document is
to qualify the Module based on the [***] technology 
  

	2.	TABLE OF CONTENTS 

  

					
	 1.
	 	PURPOSE AND SCOPE	  	3
	 2.
	 	TABLE OF CONTENTS	  	3
	 3.
	 	APPLICABLE DOCUMENTS	  	4
	 4.
	 	DEFINITIONS	  	4
	 5.
	 	SUPPLIES AND MATERIALS	  	4
	 6.
	 	EQUIPMENT	  	4
	 7.
	 	SAFETY	  	4
	 8.
	 	ENVIRONMENTAL PROTECTION	  	4
	 9.
	 	NEW TECHNOLOGY AND QUALIFICATION VEHICLE DESCRIPTION	  	5
	 9.1
	 	General technology	  	5
	 9.2
	 	Process flow Documentation	  	5
	 9.3
	 	Qualifying vehicle description	  	5
	 10.
	 	JUSTIFICATION FOR THE NEW PROCESS	  	6
	 10.1
	 	Business	  	6
	 10.2
	 	Technology	  	6
	 11.
	 	GENERAL	  	6
	 12.
	 	QUALIFICATION PLAN	  	6
	 12.1.
	 	On Line Process Monitor	  	6
	 12.2.
	 	Electrical Tests	  	6
	 12.3.
	 	Duty Cycle	  	7
	 12.4.
	 	Process Qualification	  	7
	 12.4.1.
	 	 [***]	  	7
	 12.4.2
	 	 [***]	  	7
	 12.4.3.
	 	 [***]	  	7
	 12.5.
	 	Standard Evaluation Circuit (SEC)- [***]	  	8
	 12.5.1.
	 	 [***]	  	8
	 12.6.
	 	Technology release	  	10
	 13.
	 	PROCESS CHANGE APPROVAL FORM	  	10

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	3.	APPLICABLE DOCUMENTS 

  

			
	 Document Name
	  	 Document Number

	 Tower Semiconductor Manufacturing Safety Procedures
	  	[***]
	 Tower’s Environmental Quality Master Specifications (QMS)
	  	[***]
	 Reliability Requirements for Qualification of a New Process
	  	[***]
	 Reliability Requirements for Qualification of a New Process Module
	  	[***]
	 Process Qualification Report, [***]
	  	[***]
		
	 Design Rules for [***]
	  	[***]
	 Design Rules For [***]
	  	[***]

  

	4.	DEFINITIONS 

  

			
	 LV
	 	Low Voltage
	 HV
	 	High Voltage
	 RT
	 	Room Temperature
	 HTOL
	 	High Temperature OP-Life
	 LTOL
	 	Low Temperature OP-Life
	 CKBD
 LTPD
	 	 Checker Board
 Lot Tolerance Proportion
Defective

  

	5.	SUPPLIES AND MATERIALS 

 N/A 
  

	6.	EQUIPMENT 

  

			
	 Tool/Machine/Equipment
	 	 Usage

	 [***]
	 	 [***]

	 [***]
	 	 [***]

	 [***]
	 	 [***]

  

	7.	SAFETY 

 All personnel shall read and comply with
[***]. 
  

	8.	ENVIRONMENTAL PROTECTION 

 All personnel must review
their operations with reference to the requirements as noted in [***]. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	9.	NEW TECHNOLOGY AND QUALIFICATION VEHICLE DESCRIPTION 

  

	 	9.1.	General technology 

 [***]. 
  

	 	9.2.	Process flow Documentation 

 [***] 
  

	 	9.3.	Qualifying vehicle description 

 The
qualifying module/vehicle, identified as [***], is described in the following table. 
  

							
	 Device
	  	Package	 	Product size	 	Product array
	 [***]
	  	[***]	 	[***]	 	[***]
		  		 		 	

 Module [***] description 
 [***] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	10.	JUSTIFICATION FOR THE NEW PROCESS 

  

	 	10.1.	Technology. 

 This Technology is defined in Tower
Semiconductor Technology Road Map. 
  

	11.	GENERAL 

 The qualifying requirements of this new
process are described in tower semiconductor [***]. 
 Device characterization report should be available before final technology approval
will be issued. 
  

	12.	QUALIFICATION PLAN 

  

	 	12.1.	  On Line Process Monitor 

 [***]. 

 

	 	12.2.	  Electrical Tests 

 A total minimum of [***]
will be tested. 
 [***]. 
  

	 	12.3. 	Duty Cycle 

 [***]. 
  

	 	12.4.	  Process Qualification 

  

	(a)	12.4.1. [***] 

  

	 	12.5.	  Standard Evaluation Circuit (SEC)- [***] 

 [***] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	 	12.6.	 Technology release 

  

	1	Conditional approval Will be granted upon completion of the following tests:. [***] 

  

	2	Final technology release will granted upon completion of all qualification tests, excluding engineering evaluation tests. 

  

	13.	PROCESS CHANGE APPROVAL FORM 

 CONDITIONAL & FINAL
RELEASE ACCORDING TO QUAL REPORT APPROVERS LIST: 
 Project Manager 
 Reliability Physics Manager 
 Integration Manager 
 Yield & Device MGR 
 [***] 
 Eng. MGR

 Qualification Manager 
 Reliability Manager 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 Module Specifications 
 [***] 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Preliminary Module Datasheet 
 [***] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}]]